DE19216461T1 - Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon - Google Patents

Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon Download PDF

Info

Publication number
DE19216461T1
DE19216461T1 DE19216461.4T DE19216461T DE19216461T1 DE 19216461 T1 DE19216461 T1 DE 19216461T1 DE 19216461 T DE19216461 T DE 19216461T DE 19216461 T1 DE19216461 T1 DE 19216461T1
Authority
DE
Germany
Prior art keywords
isolated polynucleotide
polynucleotide
nucleic acid
nucleotide
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19216461.4T
Other languages
English (en)
Inventor
Antonin De Fougerolles
Atanu Roy
Jason P. SCHRUM
Suhaib Siddiqi
Paul Hatala
Stephane Bancel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19216461(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of DE19216461T1 publication Critical patent/DE19216461T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Abstract

Isoliertes Polynukleotid, das für ein Polypeptid von Interesse codiert, wobei das isolierte Polynukleotid Folgendes umfasst:(a) eine Sequenz mit einer Anzahl n verknüpfter Nukleoside oder Nukleotide, die mindestens ein gegenüber der chemischen Struktur eines A-, G-, U- oder C-Nukleosids oder -Nukleotids modifiziertes Nukleosid oder Nukleotid umfasst,(b) eine 5'-UTR,(c) eine 3'-UTR und(d) mindestens eine 5'-Cap-Struktur,wobei das mindestens eine modifizierte Nukleosid oder Nukleotid 1-Methylpseudouridin umfasst und nicht Pseudouridin oder 5-Methylcytidin ist;wobei das Polynukleotid im Vergleich zu der zellulären angeborenen Immunantwort, die durch eine entsprechende unmodifizierte Nukleinsäure induziert wird, eine geringere zelluläre angeborene Immunantwort zeigt, wenn es in eine Zellpopulation eingeführt wird.

Claims (11)

  1. Isoliertes Polynukleotid, das für ein Polypeptid von Interesse codiert, wobei das isolierte Polynukleotid Folgendes umfasst: (a) eine Sequenz mit einer Anzahl n verknüpfter Nukleoside oder Nukleotide, die mindestens ein gegenüber der chemischen Struktur eines A-, G-, U- oder C-Nukleosids oder -Nukleotids modifiziertes Nukleosid oder Nukleotid umfasst, (b) eine 5'-UTR, (c) eine 3'-UTR und (d) mindestens eine 5'-Cap-Struktur, wobei das mindestens eine modifizierte Nukleosid oder Nukleotid 1-Methylpseudouridin umfasst und nicht Pseudouridin oder 5-Methylcytidin ist; wobei das Polynukleotid im Vergleich zu der zellulären angeborenen Immunantwort, die durch eine entsprechende unmodifizierte Nukleinsäure induziert wird, eine geringere zelluläre angeborene Immunantwort zeigt, wenn es in eine Zellpopulation eingeführt wird.
  2. Isoliertes Polynukleotid nach Anspruch 1, das ferner einen Poly-A-Schwanz umfasst.
  3. Isoliertes Polynukleotid nach Anspruch 1 oder 2, das gereinigt ist.
  4. Isoliertes Polynukleotid nach einem der Ansprüche 1-3, wobei die mindestens eine 5'-Cap-Struktur aus der Gruppe bestehend aus CapO, Cap1, ARCA, Inosin, N1-Methylguanosin, 2'-Fluorguanosin, 7-Deazaguanosin, 8-Oxoguanosin, 2-Aminoguanosin, LNA-Guanosin und 2-Azidoguanosin ausgewählt ist.
  5. Isoliertes Polynukleotid nach einem der Ansprüche 1-4, wobei die modifizierte Nukleinsäure im Vergleich zu einer entsprechenden unmodifizierten Nukleinsäure einen geringeren Abbau in einer Zelle zeigt, in welche die Nukleinsäure eingeführt wird.
  6. Isoliertes Polynukleotid nach einem der Ansprüche 2-5, wobei die Poly-A-Region 150 bis 165 Nukleotide lang ist.
  7. Isoliertes Polynukleotid nach einem der Ansprüche 1-6, wobei das Polynukleotid ein Protein:Zytokin-Verhältnis größer 100 aufweist; und wobei das Protein:Zytokin-Verhältnis das Verhältnis der Menge an codiertem Polypeptid, das in einer Zelle, einem Gewebe oder einem Organismus produziert wird, zu der Menge an einem oder mehreren Zytokinen ist, deren Expression in der Zelle, dem Gewebe oder dem Organismus als Folge einer Verabreichung des Polynukleotids oder eines Kontakts mit dem Polynukleotid ausgelöst wird.
  8. Isoliertes Polynukleotid nach einem der Ansprüche 1-7, wobei Uridin in dem Polynukleotid zu etwa 100 % durch das 1-Methylpseudouridin ersetzt ist.
  9. Pharmazeutische Zusammensetzung, die das isolierte Polynukleotid nach einem der Ansprüche 1-8 und einen pharmazeutisch verträglichen Exzipienten umfasst.
  10. Isoliertes Polynukleotid nach einem der Ansprüche 1-8 oder pharmazeutische Zusammensetzung nach Anspruch 9 zur Verwendung in einem therapeutischen Verfahren zum Erhöhen des Spiegels eines Peptids von Interesse bei einem Säuger-Subjekt, wobei das Verfahren ein Verabreichen des Polynukleotids an das Subjekt umfasst.
  11. Isoliertes Polynukleotid oder pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 10, wobei bei dem Verfahren die Spiegel des Polypeptids von Interesse in dem Serum des Säugers mindestens 50 pg/ml mindestens zwei Stunden nach der Verabreichung betragen oder vorzugsweise über 50 oder mehr bevorzugt über 60 pg/ml für mindestens 72 Stunden nach der Verabreichung bleiben.
DE19216461.4T 2011-10-03 2012-10-03 Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon Pending DE19216461T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542533P 2011-10-03 2011-10-03
US201161542533P 2011-10-03
EP19216461.4A EP3682905B1 (de) 2011-10-03 2012-10-03 Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon

Publications (1)

Publication Number Publication Date
DE19216461T1 true DE19216461T1 (de) 2021-10-07

Family

ID=48044115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19216461.4T Pending DE19216461T1 (de) 2011-10-03 2012-10-03 Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon

Country Status (24)

Country Link
US (4) US9428535B2 (de)
EP (4) EP3492109B1 (de)
JP (6) JP6113737B2 (de)
KR (2) KR20190099538A (de)
CN (2) CN110511939A (de)
AU (5) AU2012318752B2 (de)
CA (1) CA2850624A1 (de)
CY (1) CY1125029T1 (de)
DE (1) DE19216461T1 (de)
DK (1) DK3682905T3 (de)
ES (1) ES2911677T3 (de)
HK (1) HK1200730A1 (de)
HR (1) HRP20220250T1 (de)
HU (1) HUE057725T2 (de)
IL (2) IL231808B (de)
LT (1) LT3682905T (de)
MX (1) MX354267B (de)
PL (1) PL3682905T3 (de)
PT (1) PT3682905T (de)
RS (1) RS62993B1 (de)
RU (2) RU2707251C2 (de)
SG (2) SG10201602654SA (de)
SI (1) SI3682905T1 (de)
WO (1) WO2013052523A1 (de)

Families Citing this family (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
MX2013000164A (es) 2010-07-06 2013-03-05 Novartis Ag Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
CA2809851A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
EP4098324A1 (de) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigenfreisetzungsplattformen
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012159754A2 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
ES2911653T3 (es) 2011-06-08 2022-05-20 Translate Bio Inc Composiciones de nanopartículas lipídicas y métodos para el suministro de ARNm
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CA2858148C (en) 2011-12-05 2023-03-14 Factor Bioscience Inc. Methods and products for transfecting cells
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP3501550A1 (de) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
JP6460983B2 (ja) 2012-07-03 2019-01-30 バイオマリン テクノロジーズ ベー．フェー． 筋ジストロフィー患者の治療のためのオリゴヌクレオチド
EP2885419A4 (de) 2012-08-14 2016-05-25 Moderna Therapeutics Inc Enzyme und polymerasen für rna-synthese
US20150307542A1 (en) * 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2914728B1 (de) 2012-11-01 2020-07-08 Factor Bioscience Inc. Verfahren und produkte zur expression von proteinen in zellen
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
EP2925348B1 (de) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualisierte impfstoffe gegen krebs
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
LT2970456T (lt) 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
AU2014236305B2 (en) 2013-03-14 2019-01-17 Ethris Gmbh CFTR mRNA compositions and related methods and uses
EP2971010B1 (de) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
EP3750903A1 (de) 2013-03-14 2020-12-16 Translate Bio, Inc. Ribonukleinsäuren mit 4'-thio-modifizierten nukleotiden und zugehörige verfahren
EP2983804A4 (de) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ionenaustauschreinigung von mrna
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
SI2972360T1 (en) 2013-03-15 2018-08-31 Translate Bio, Inc. Synergistic improvement in the delivery of nucleic acids via mixed formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2971033B8 (de) 2013-03-15 2019-07-10 ModernaTX, Inc. Herstellungsverfahren zur herstellung von rna-transkripten
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
MX2015015221A (es) 2013-05-03 2016-07-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos y macromoléculas terapéuticas para efectos farmacodinámicos reducidos o intensificados.
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3003306B1 (de) 2013-06-04 2020-08-26 Selecta Biosciences, Inc. Wiederholte verabreichung von nicht-immunosupressiven antigenspezifischen immuntherapeutika
CN103254253B (zh) * 2013-06-06 2015-11-18 济南卡博唐生物科技有限公司 一种制备双丙酮-d-阿洛糖的方法
EA036400B1 (ru) 2013-06-28 2020-11-06 Этрис Гмбх Композиции для введения рнк в клетки
SI3019619T1 (sl) 2013-07-11 2021-12-31 Modernatx, Inc. Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3043826A4 (de) * 2013-09-13 2017-05-24 Moderna Therapeutics, Inc. Polynukleotidzusammensetzungen mit aminosäuren
CN103467509A (zh) * 2013-09-27 2013-12-25 成都爱博协诺化学技术有限公司 肿瘤药物中间体的合成方法
EP3052106A4 (de) * 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
WO2015051173A2 (en) * 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
EP3052511A4 (de) * 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynukleotidmoleküle und verwendungen davon
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
EP3542802A1 (de) 2013-11-01 2019-09-25 CureVac AG Modifizierte rna mit verminderten immunstimulierenden eigenschaften
SI3594348T1 (sl) 2013-11-22 2022-04-29 Mina Therapeutics Limited Sestavki kratko aktivirajoče rna c/ebp alfa in postopki uporabe
US20150167017A1 (en) * 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3082760A1 (de) 2013-12-19 2016-10-26 Novartis AG Leptin-mrna-zusammensetzungen und -formulierungen
CA2937036A1 (en) 2014-01-31 2015-08-06 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
CN106414749A (zh) 2014-02-26 2017-02-15 埃泽瑞斯公司 用于胃肠给予rna的组合物
CN103784422B (zh) * 2014-02-28 2016-03-02 重庆医科大学附属第二医院 一种载rtPA纳米粒及其制备方法
EP3981437A1 (de) 2014-04-23 2022-04-13 ModernaTX, Inc. Nukleinsäureimpfstoffe
PT3155129T (pt) 2014-06-10 2019-05-16 Curevac Ag Método para potenciar a produção de arn
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CN111588695A (zh) * 2014-06-24 2020-08-28 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
JP2017524357A (ja) 2014-07-16 2017-08-31 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． キメラポリヌクレオチド
WO2016011222A2 (en) * 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
CN104211740B (zh) * 2014-08-20 2016-10-26 济南尚博生物科技有限公司 一种n4-苯甲酰基-d-胞苷的制备方法
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
US20160130567A1 (en) 2014-11-02 2016-05-12 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
EP3218508A4 (de) 2014-11-10 2018-04-18 Modernatx, Inc. Multiparametrische nukleinsäureoptimierung
EP3041948B1 (de) 2014-11-10 2019-01-09 Modernatx, Inc. Alternative nukleinsäuremoleküle mit reduziertem uracilgehalt und verwendungen davon
EP3034539A1 (de) 2014-12-19 2016-06-22 Ethris GmbH Zusammensetzungen zur Einführung von Nukleinsäure in Zellen
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3543339A1 (de) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nukleinsäureprodukte und verabreichungsverfahren dafür
US20180208957A1 (en) 2015-04-30 2018-07-26 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
JP6893177B2 (ja) 2015-05-15 2021-06-23 キュアバック アーゲー 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ）
EP4098743A1 (de) 2015-05-29 2022-12-07 CureVac AG Verfahren zum hinzufügen von kappenstrukturen zu rns mittels immobilisierter enzyme
EP3744843A1 (de) 2015-05-29 2020-12-02 CureVac Real Estate GmbH Verfahren zur herstellung und reinigung von rna mit mindestens einem schritt mit einer tangentialen flussfiltration
CN108138187B (zh) 2015-08-10 2022-07-19 库瑞瓦格房地产有限公司 增加环状dna分子复制的方法
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
SI3954225T1 (sl) 2015-09-21 2024-03-29 Trilink Biotechnologies, Llc Iniciacijski omejeni oligonukleotidni primer za sintezo 5'-omejenih RNK
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2017066791A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
PL3718565T3 (pl) 2015-10-22 2022-09-19 Modernatx, Inc. Szczepionki przeciwko wirusom układu oddechowego
AU2016342376A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
ES2763822T3 (es) 2015-12-09 2020-06-01 Novartis Ag Análisis exento de marcas de la eficacia de la adición de caperuzas al arn utilizando rnasa h, sondas y cromatografía líquida/espectrometría de masas
EP3394280A1 (de) 2015-12-23 2018-10-31 CureVac AG Verfahren für rna-in-vitro-transkription mittels eines puffers mit dicarboxylsäure oder tricarbonsäure oder einem salz davon
WO2017112943A1 (en) 2015-12-23 2017-06-29 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3417069A1 (de) 2016-02-15 2018-12-26 CureVac AG Verfahren zur analyse von nebenprodukten von rna-in-vitro-transkription
EP3423595A1 (de) 2016-03-03 2019-01-09 CureVac AG Rns-analyse durch gesamthydrolyse
WO2017162297A1 (en) 2016-03-24 2017-09-28 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
CA3018904C (en) * 2016-03-31 2024-04-02 Ethris Gmbh Novel minimal utr sequences
EP3825400A1 (de) 2016-04-08 2021-05-26 Translate Bio Ma, Inc. Multimere codierende nukleinsäure und verwendungen davon
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3442590A2 (de) 2016-04-13 2019-02-20 Modernatx, Inc. Lipidzusammensetzungen und deren verwendungen zur intratumoralen verabreichung von polynukleotiden
MA45041A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1
SG11201810256XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding relaxin
US10993918B2 (en) 2016-05-18 2021-05-04 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of Citrullinemia type 2
CN109476718B (zh) 2016-05-18 2023-07-04 莫得纳特斯公司 编码免疫调节多肽的mrna的组合及其用途
CA3024470A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
AU2017266932B2 (en) 2016-05-18 2023-04-20 Modernatx, Inc. Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
KR101892086B1 (ko) 2016-05-19 2018-08-27 주식회사 삼양사 옥심에스테르 유도체 화합물, 이를 포함하는 광중합 개시제, 및 감광성 조성물
CN109312313A (zh) 2016-06-13 2019-02-05 川斯勒佰尔公司 用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
CN109526226A (zh) 2016-07-07 2019-03-26 鲁比厄斯治疗法股份有限公司 与表达外源rna的治疗性细胞体系有关的组合物和方法
EP3481430A4 (de) 2016-07-11 2020-04-01 Translate Bio Ma, Inc. Nukleinsäurekonjugate und verwendungen davon
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
US10093706B2 (en) 2017-01-30 2018-10-09 Indiana University Research And Technology Corporation Dominant positive hnRNP-E1 polypeptide compositions and methods
WO2018141371A1 (en) 2017-01-31 2018-08-09 Curevac Ag Purification and/or formulation of rna
WO2018144778A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Polynucleotide secondary structure
KR20180090135A (ko) 2017-02-02 2018-08-10 주식회사 삼양사 신규한 옥심에스테르 비페닐 화합물, 이를 포함하는 광중합 개시제 및 감광성 조성물
CN110662838A (zh) 2017-02-22 2020-01-07 克里斯珀医疗股份公司 用于基因编辑的组合物和方法
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
EP3589308A1 (de) 2017-02-28 2020-01-08 Sanofi Therapeutische rns
EP3589290A4 (de) 2017-02-28 2020-12-30 Arcturus Therapeutics, Inc. Translatierbare moleküle und deren synthese
JP2020515258A (ja) 2017-03-31 2020-05-28 アジェノビア コーポレーション 抗ウイルス治療剤
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
WO2018222926A1 (en) 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type iii
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
MA49395A (fr) 2017-06-14 2020-04-22 Modernatx Inc Polynucléotides codant pour le facteur viii de coagulation
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3679138B1 (de) 2017-09-08 2023-03-22 MiNA Therapeutics Limited Hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
US20210180053A1 (en) 2017-11-01 2021-06-17 Novartis Ag Synthetic rnas and methods of use
MA50801A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie
CA3079543A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
CA3079428A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
KR101991903B1 (ko) 2017-12-07 2019-10-01 주식회사 삼양사 카바졸 옥심에스테르 유도체 화합물 및 이를 포함하는 광중합 개시제와 감광성 조성물
WO2019116346A1 (en) 2017-12-15 2019-06-20 Novartis Ag Polya tail length analysis of rna by mass spectrometry
CA3084061A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
MA51523A (fr) 2018-01-05 2020-11-11 Modernatx Inc Polynucléotides codant pour des anticorps anti-virus du chikungunya
SI3773689T1 (sl) 2018-04-11 2023-02-28 Enterome S.A. Antigenski peptidi za preprečevanje in zdravljenje raka
EP3775211B1 (de) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna kompositionen und methoden zu deren verwendung
WO2019204210A1 (en) * 2018-04-16 2019-10-24 Georgia Tech Research Corporation Mrna driven expression of rna editors for treatment of pathologies
CN112153985B (zh) 2018-04-25 2024-03-01 埃泽瑞斯公司 用于颗粒制剂的防冻剂
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112585268A (zh) 2018-06-28 2021-03-30 克里斯珀医疗股份公司 通过插入供体多核苷酸用于基因组编辑的组合物和方法
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN113164556A (zh) 2018-08-30 2021-07-23 特纳亚治疗股份有限公司 用心肌蛋白和ascl1进行的心脏细胞重编程
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2020056147A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
MA53608A (fr) 2018-09-13 2021-07-21 Modernatx Inc Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
MA53734A (fr) 2018-09-27 2021-08-04 Modernatx Inc Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
CA3114892A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
EP3870600A1 (de) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er-abstimmbare proteinregulierung
AU2019394996A1 (en) 2018-12-06 2021-07-29 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
KR102228630B1 (ko) 2018-12-28 2021-03-16 주식회사 삼양사 카바졸 멀티 베타 옥심에스테르 유도체 화합물 및 이를 포함하는 광중합 개시제와 포토레지스트 조성물
GB2580963B (en) * 2019-02-01 2021-03-31 Hemispherian As Cancer therapies
CA3132840A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
KR20210142678A (ko) * 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
US20220226438A1 (en) 2019-05-08 2022-07-21 Astrazeneca Ab Compositions for skin and wounds and methods of use thereof
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3997226A1 (de) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN112390838A (zh) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 一种改性核苷及其合成方法
EP4017539A1 (de) 2019-08-19 2022-06-29 MiNA Therapeutics Limited Oligonukleotidkonjugatzusammensetzungen und verwendungsverfahren
AU2020333968A1 (en) 2019-08-22 2022-03-31 New England Biolabs, Inc. Cleavage of single stranded DNA having a modified nucleotide
CN112714795A (zh) 2019-08-23 2021-04-27 新英格兰生物实验室公司 酶促rna加帽方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AU2020343516A1 (en) 2019-09-06 2022-03-10 Crispr Therapeutics Ag Genetically engineered T cells having improved persistence in culture
CA3155028A1 (en) * 2019-10-18 2021-04-22 Daiichi Sankyo Company, Limited Method for producing bicyclic phosphoramidite
RS65262B1 (sr) 2019-11-15 2024-03-29 Enterome S A Antigenski peptidi za prevenciju i lečenje maligniteta b ćelija
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
AU2021230476A1 (en) 2020-03-02 2022-10-20 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed microRNAs
WO2021202788A2 (en) * 2020-04-03 2021-10-07 Ionis Pharmaceuticals, Inc. Modified oligomeric compounds and uses thereof
EP3901261A1 (de) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirusimpfstoff
AU2021285812A1 (en) 2020-06-01 2023-01-05 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
CN116368226A (zh) * 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
WO2022064428A1 (en) 2020-09-23 2022-03-31 Crispr Therapeutics Ag Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
WO2022090752A1 (en) 2020-10-26 2022-05-05 Pécsi Tudományegyetem Vaccine platform
JP2023549787A (ja) 2020-11-12 2023-11-29 インターベット インターナショナル ベー． フェー． キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022106860A1 (en) 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
BR112023012303A2 (pt) 2020-12-22 2024-02-15 CureVac SE Vacina de rna contra variantes de sars-cov-2
US20220193134A1 (en) 2020-12-23 2022-06-23 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CN112725346A (zh) * 2021-01-22 2021-04-30 青岛大学 一种增加尿酸排泄的修饰mRNA序列及其应用
AU2021424650A1 (en) 2021-01-27 2023-08-17 New England Biolabs, Inc. Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
US11028379B1 (en) 2021-01-27 2021-06-08 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
CN116887812A (zh) 2021-02-26 2023-10-13 埃泽瑞斯公司 用于气溶胶形成的制剂以及用于递送核酸的气溶胶
KR20230150319A (ko) 2021-03-01 2023-10-30 사이롬 게임베하 iRhom2에 대한 인간화 항체
WO2022189967A1 (en) 2021-03-09 2022-09-15 Crispr Therapeutics Ag Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
EP4314260A1 (de) 2021-03-24 2024-02-07 Modernatx, Inc. Lipidnanopartikel und polynukleotide zur codierung von ornithintranscarbamylase zur behandlung von ornithintranscarbamylasemangel
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
EP4314292A1 (de) 2021-03-26 2024-02-07 MiNA Therapeutics Limited Tmem173-sarna-zusammensetzungen und verfahren zur verwendung
CA3213771A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
CN112979721B (zh) * 2021-03-29 2023-05-09 江苏集萃分子工程研究院有限公司 一种高纯度抗肿瘤药曲氟胞苷的制备方法
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
AU2022253064A1 (en) 2021-04-09 2023-10-19 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
CA3177712A1 (en) 2021-06-02 2022-12-02 Lyell Immunopharma, Inc. Nr4a-deficient cells expressing c-jun and uses thereof
CN113372432A (zh) * 2021-06-15 2021-09-10 深圳市臻质医疗科技有限公司 一种基于化学修饰mRNA编码蛋白因子诱导和/或增强软骨损伤修复的方法
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
TW202328444A (zh) 2021-07-26 2023-07-16 瑞士商Ｃｒｉｓｐｒ治療公司 用於製造基因工程化ｃａｒ－ｔ細胞之方法
CN113651865A (zh) * 2021-08-19 2021-11-16 上海兆维科技发展有限公司 一种去除四丁基氟化铵的方法
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20230128917A1 (en) 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023069498A1 (en) 2021-10-22 2023-04-27 Senda Biosciences, Inc. Mrna vaccine composition
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023077170A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Polynucleotides encoding integrin beta-6 and methods of use thereof
WO2023084399A1 (en) 2021-11-09 2023-05-19 Crispr Therapeutics Ag Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
WO2023119201A2 (en) 2021-12-22 2023-06-29 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122331A2 (en) * 2021-12-23 2023-06-29 Optimeos Life Sciences, Inc. Nanoparticles and methods of production for the encapsulation of nucleic acids
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
TW202345864A (zh) 2022-02-18 2023-12-01 美商現代公司 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230287376A1 (en) 2022-03-11 2023-09-14 New England Biolabs, Inc. Immobilized enzyme compositions and methods
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
US20230303713A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023185812A1 (zh) * 2022-03-29 2023-10-05 上海吉量医药工程有限公司 乙酰化胞嘧啶三磷酸盐及其中间体的制备方法
CN114736260A (zh) * 2022-03-29 2022-07-12 上海吉量医药工程有限公司 一种三磷酸核苷酸盐的制备方法
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023196950A1 (en) 2022-04-07 2023-10-12 New England Biolabs, Inc. Methods of higher fidelity rna synthesis
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2023223183A1 (en) 2022-05-16 2023-11-23 Crispr Therapeutics Ag Picornaviral vectors for gene editing
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US20240041757A1 (en) 2022-06-17 2024-02-08 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248110A1 (en) 2022-06-20 2023-12-28 Crispr Therapeutics Ag Base editing proteins and uses thereof
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
EP4327829A1 (de) 2022-08-26 2024-02-28 Ethris GmbH Stabilisierung von lipid- oder lipidoidnanopartikelsuspensionen
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
CN116284189B (zh) * 2023-05-16 2023-08-08 深圳赛陆医疗科技有限公司 一种合成MANT-GTPγS的方法

Family Cites Families (1117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008526A (en) 1932-11-03 1935-07-16 Wappler Frederick Charles Method and means for treating living tissue
US3467096A (en) 1966-04-12 1969-09-16 Ferrell S Horn Multiple hypodermic syringe arrangement
BE757653A (fr) 1969-10-21 1971-04-16 Ugine Kuhlmann Nouveaux medicaments derives d'acides nucleiques et procedes pour leur preparation
BE786542A (fr) 1971-07-22 1973-01-22 Dow Corning Dispositif d'aspiration permettant d'obtenir des echantillons de cellules
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4474569A (en) 1982-06-28 1984-10-02 Denver Surgical Developments, Inc. Antenatal shunt
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0204401A1 (de) 1985-04-09 1986-12-10 Biogen, Inc. Verfahren zur Verbesserung der Ausbeute von in einer Wirtzelle hergestellten Polypeptiden durch mRNA-Stabilisierung
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
JP2774121B2 (ja) 1987-07-31 1998-07-09 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 標的ポリヌクレオチド配列の選択的増幅
US6090591A (en) 1987-07-31 2000-07-18 The Board Of Trustees Of The Leland Stanford Junior University Selective amplification of target polynucleotide sequences
DE68908054T2 (de) 1988-01-21 1994-03-10 Genentech Inc Verstärkung und nachweis von nukleinsäuresequenzen.
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
DE68923027D1 (de) 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
US5168038A (en) 1988-06-17 1992-12-01 The Board Of Trustees Of The Leland Stanford Junior University In situ transcription in cells and tissues
US5021335A (en) 1988-06-17 1991-06-04 The Board Of Trustees Of The Leland Stanford Junior University In situ transcription in cells and tissues
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
EP0465529B1 (de) 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5012818A (en) 1989-05-04 1991-05-07 Joishy Suresh K Two in one bone marrow surgical needle
IE66597B1 (en) 1989-05-10 1996-01-24 Akzo Nv Method for the synthesis of ribonucleic acid (RNA)
US5240855A (en) 1989-05-12 1993-08-31 Pioneer Hi-Bred International, Inc. Particle gun
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
NO904633L (no) 1989-11-09 1991-05-10 Molecular Diagnostics Inc Amplifikasjon av nukleinsyrer ved transkriberbar haarnaalsprobe.
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5215899A (en) 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5194370A (en) 1990-05-16 1993-03-16 Life Technologies, Inc. Promoter ligation activated transcription amplification of nucleic acid sequences
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン，インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US6140496A (en) 1990-10-09 2000-10-31 Benner; Steven Albert Precursors for deoxyribonucleotides containing non-standard nucleosides
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US6100024A (en) 1991-02-08 2000-08-08 Promega Corporation Methods and compositions for nucleic acid detection by target extension and probe amplification
EP1097945B1 (de) 1991-03-18 2007-07-04 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
KR100249937B1 (ko) 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5199441A (en) 1991-08-20 1993-04-06 Hogle Hugh H Fine needle aspiration biopsy apparatus and method
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0625049A4 (de) 1992-01-23 1995-07-12 Vical Inc Ex vivo gentransfer.
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5514545A (en) 1992-06-11 1996-05-07 Trustees Of The University Of Pennsylvania Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH07509365A (ja) 1992-07-31 1995-10-19 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング ポリヌクレオチド類の３’末端に特定配列を導入する方法
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1994009838A1 (en) 1992-11-04 1994-05-11 Denver Biomaterials, Inc. Apparatus for removal of pleural effusion fluid
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US7135312B2 (en) 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5851829A (en) 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5672491A (en) 1993-09-20 1997-09-30 The Leland Stanford Junior University Recombinant production of novel polyketides
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US6096503A (en) 1993-11-12 2000-08-01 The Scripps Research Institute Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
DK0668350T4 (da) 1994-02-16 2009-02-23 Us Gov Health & Human Serv Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
JP3482209B2 (ja) 1994-03-18 2003-12-22 ジェロン・コーポレーション オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
HU226874B1 (en) 1994-05-18 2010-01-28 Bayer Bioscience Gmbh Dna sequences coding for enzymes capable of facilitating the synthesis of linear alfa-1,4 glucans in plants, fungi and microorganisms
WO1995033835A1 (en) 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5665545A (en) 1994-11-28 1997-09-09 Akzo Nobel N.V. Terminal repeat amplification method
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
WO1996021023A1 (en) 1995-01-06 1996-07-11 Centrum Voor Plantenveredelings- En Reproduktieonderzoek (Cpro - Dlo) Dna sequences encoding carbohydrate polymer synthesizing enzymes and method for producing transgenic plants
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5824497A (en) * 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
EP0727187B1 (de) 1995-02-15 2003-08-06 Joseph Eldor Spinalnadel mit mehreren Löchern
EP0735144B1 (de) 1995-03-28 2002-06-05 Japan Science and Technology Corporation Verfahren zur molekularen Indexierung von Genen unter Verwendung von Restriktionsenzymen
US5869230A (en) 1995-03-30 1999-02-09 Beth Israel Hospital Association Gene transfer into the kidney
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
WO1997011085A1 (en) 1995-09-19 1997-03-27 University Of Massachusetts Inhibited biological degradation of oligodeoxynucleotides
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6132988A (en) 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5962271A (en) 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
AU1874397A (en) 1996-02-16 1997-09-02 Stichting Rega Vzw Hexitol containing oligonucleotides and their use in antisense strategies
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
US6090391A (en) 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
US6300487B1 (en) 1996-03-19 2001-10-09 Cell Therapuetics, Inc. Mammalian lysophosphatidic acid acyltransferase
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1997046680A1 (en) 1996-06-05 1997-12-11 Chiron Corporation Dna encoding dp. 75 and a process for its use
US7329741B2 (en) 1996-06-05 2008-02-12 Chiron Corporation Polynucleotides that hybridize to DP-75 and their use
CA2258568A1 (en) 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
EP0925088A2 (de) 1996-06-28 1999-06-30 Sontra Medical, L.P. Ultraschallsteigerung des transdermalen transports
US5677124A (en) 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
ATE318915T1 (de) 1996-09-24 2006-03-15 Tanox Inc Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
EP0930893B1 (de) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulierende oligonucleotidekonjugate
EP0839912A1 (de) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US5759179A (en) 1996-12-31 1998-06-02 Johnson & Johnson Medical, Inc. Needle and valve assembly for use with a catheter
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
ATE342916T1 (de) 1997-02-07 2006-11-15 Merck & Co Inc Synthetische hiv gag gene
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5914269A (en) 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
AU6972798A (en) 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US5958688A (en) 1997-04-28 1999-09-28 The Trustees Of The University Of Pennsylvania Characterization of mRNA patterns in neurites and single cells for medical diagnosis and therapeutics
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989911A (en) 1997-05-09 1999-11-23 University Of Massachusetts Site-specific synthesis of pseudouridine in RNA
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6124091A (en) 1997-05-30 2000-09-26 Research Corporation Technologies, Inc. Cell growth-controlling oligonucleotides
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CN1275085A (zh) 1997-07-21 2000-11-29 法玛西雅和厄普约翰公司 靶细胞的定向细胞溶解、引起细胞溶解的试剂和组合物以及可用于制备这些试剂的化合物
AU8763898A (en) 1997-07-31 1999-02-22 St. Elizabeth's Medical Center Of Boston, Inc. Method for the treatment of grafts
AU752725B2 (en) 1997-09-18 2002-09-26 Trustees Of The University Of Pennsylvania, The Attenuated vif DNA immunization cassettes for genetic vaccines
EP1021549A2 (de) 1997-09-19 2000-07-26 Sequitur, Inc. Sense mrna therapie
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP2001519162A (ja) 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート 動物細胞にｒｎａを導入して発現させる方法
CA2306796A1 (en) 1997-10-20 1999-04-29 Genzyme Transgenics Corporation Novel modified msp-1 nucleic acid sequences and methods for increasing mrna levels and protein expression in cell systems
US6019747A (en) 1997-10-21 2000-02-01 I-Flow Corporation Spring-actuated infusion syringe
AU1275899A (en) 1997-10-24 1999-05-17 Megabios Corporation Methods for preparing polynucleotide transfection complexes
EP1987845B1 (de) 1997-11-20 2012-03-21 Vical Incorporated Behandlung von Krebs mithilfe Cytokin-exprimierender Polynukleotide und Zusammensetzungen dafür
US7655777B2 (en) 1997-11-24 2010-02-02 Monsanto Technology Llc Nucleic acid molecules associated with the tocopherol pathway
US6267987B1 (en) 1997-12-12 2001-07-31 Samyang Corporation Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
US6517869B1 (en) 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
WO1999033982A2 (en) 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
CA2317549C (en) 1998-01-05 2006-04-11 University Of Washington Composition for enhancing transport through lipid-containing membranes, and uses thereof
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
AU740999B2 (en) 1998-01-08 2001-11-22 Sontra Medical, Inc. Sonophoretic enhanced transdermal transport
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6365346B1 (en) 1998-02-18 2002-04-02 Dade Behring Inc. Quantitative determination of nucleic acid amplification products
US5955310A (en) 1998-02-26 1999-09-21 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide in a bacillus cell
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
GB9808327D0 (en) 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US7521178B1 (en) 1998-04-23 2009-04-21 Takara Bio Inc. Method for synthesizing DNA
US20020064517A1 (en) 1998-04-30 2002-05-30 Stewart A. Cederholm-Williams Fibrin sealant as a transfection/transformation vehicle for gene therapy
US20090208418A1 (en) 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
US6177274B1 (en) 1998-05-20 2001-01-23 Expression Genetics, Inc. Hepatocyte targeting polyethylene glyco-grafted poly-L-lysine polymeric gene carrier
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
MXPA01000271A (es) 1998-07-13 2002-10-17 Expression Genetics Inc Analogo de poliester de poli-lisina como un portador para el suministro de genes, soluble, biodegradable.
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6222030B1 (en) 1998-08-03 2001-04-24 Agilent Technologies, Inc. Solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection
CN101695574A (zh) 1998-08-11 2010-04-21 拜奥根Idec公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
GB9817662D0 (en) 1998-08-13 1998-10-07 Crocker Peter J Substance delivery
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
CA2348779A1 (en) 1998-11-03 2000-05-11 Yale University Multidomain polynucleotide molecular sensors
CN1679934B (zh) 1998-11-09 2012-09-05 生物基因Idec公司 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤
KR20010099788A (ko) 1998-11-09 2001-11-09 케네쓰 제이. 울코트 Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법
WO2000027340A2 (en) 1998-11-12 2000-05-18 The Children's Medical Center Corporation USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
EP1141376A4 (de) 1998-12-23 2002-03-13 Human Genome Sciences Peptidoglycan-erkennungsproteine
US6255476B1 (en) 1999-02-22 2001-07-03 Pe Corporation (Ny) Methods and compositions for synthesis of labelled oligonucleotides and analogs on solid-supports
CA2364921A1 (en) 1999-02-22 2000-08-31 European Molecular Biology Laboratory Translation system
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
EP1985639B1 (de) 1999-04-09 2013-08-14 Life Technologies AS Verfahren zur Herstellung monodisperser Polymerteilchen
KR20020011985A (ko) 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
WO2000075356A1 (en) 1999-06-04 2000-12-14 Lin Shi Lung Rna polymerase chain reaction
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6303573B1 (en) 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
AU776268B2 (en) 1999-06-08 2004-09-02 Aventis Pasteur Immunostimulant oligonucleotide
EP1194167B1 (de) 1999-06-09 2009-08-19 Immunomedics, Inc. Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1196426A4 (de) 1999-06-30 2003-09-03 Advanced Cell Tech Inc Zytoplasmatischer transfer zur de-differenzierung von gefässzellen
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
CA2378653A1 (en) 1999-07-09 2001-01-18 American Home Products Corporation Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US20050112141A1 (en) 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
US20040106567A1 (en) 1999-09-07 2004-06-03 Hagstrom James E. Intravascular delivery of non-viral nucleic acid
EP1818409A1 (de) 1999-09-09 2007-08-15 CureVac GmbH Transfer von mRNA unter Verwendung von polykationischen Verbindungen
WO2001021810A1 (en) 1999-09-17 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
AU7863200A (en) 1999-10-06 2001-05-10 Quark Biotech, Inc. Method for enrichment of natural antisense messenger rna
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US6613026B1 (en) 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
US6277974B1 (en) 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US6245929B1 (en) 1999-12-20 2001-06-12 General Electric Company Catalyst composition and method for producing diaryl carbonates, using bisphosphines
WO2001046272A1 (en) 1999-12-22 2001-06-28 Basell Technology Company B.V. Alpha-olefin polymerization catalyst system which contains an aromatic silane compound
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
AU2001232485A1 (en) 2000-01-13 2001-07-24 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
WO2001055306A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2398756A1 (en) 2000-01-31 2001-08-02 Eyal Raz Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
PT1481992T (pt) 2000-02-24 2017-01-02 Lilly Co Eli Anticorpos humanizados que sequestram péptido beta-amiloide
CA2401327C (en) 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
US20020081597A1 (en) 2000-03-31 2002-06-27 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
CN1441677A (zh) 2000-03-31 2003-09-10 Idec药物公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US6565572B2 (en) 2000-04-10 2003-05-20 Sdgi Holdings, Inc. Fenestrated surgical screw and method
US6368801B1 (en) 2000-04-12 2002-04-09 Molecular Staging, Inc. Detection and amplification of RNA using target-mediated ligation of DNA by RNA ligase
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040229271A1 (en) 2000-05-19 2004-11-18 Williams Richard B. Compositions and methods for the identification and selection of nucleic acids and polypeptides
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
CA2412026A1 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
JP2004513616A (ja) 2000-06-23 2004-05-13 ワイス・ホールディングズ・コーポレイション 改変モルビリウイルスタンパク質
EP1297005B1 (de) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen chlamydia pneumoniae
US6440096B1 (en) 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
AU7569501A (en) 2000-07-21 2002-02-05 Glaxo Group Ltd Codon-optimized papilloma virus sequences
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
WO2002024873A1 (en) 2000-09-20 2002-03-28 Christopher Ralph Franks Stem cell therapy
WO2002028165A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7202226B2 (en) 2000-10-23 2007-04-10 Detroit R & D Augmentation of wound healing by elF-4E mRNA and EGF mRNA
US20030077604A1 (en) 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
WO2002040545A2 (en) 2000-11-17 2002-05-23 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
EP2336368A1 (de) 2000-12-07 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Positive eingestellte endogene Retroviren in Prostatakrebs
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
IL157003A0 (en) 2001-01-19 2004-02-08 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
EP1224943A1 (de) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin als Tumor Marker, detektiert durch auf Phagen exprimierte Antikörper
US20040110191A1 (en) 2001-01-31 2004-06-10 Winkler Matthew M. Comparative analysis of nucleic acids using population tagging
US20030186237A1 (en) 2001-02-14 2003-10-02 Baylor College Of Medicine Methods and compositions of amplifying RNA
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US7232425B2 (en) 2001-03-02 2007-06-19 Sorenson Development, Inc. Apparatus and method for specific interstitial or subcutaneous diffusion and dispersion of medication
EP1373528B1 (de) 2001-03-09 2008-08-13 Gene Stream Pty Ltd. Neue expressionsvektoren
JP2002262882A (ja) 2001-03-12 2002-09-17 Nisshinbo Ind Inc Ｒｎａの増幅法
FR2822164B1 (fr) 2001-03-19 2004-06-18 Centre Nat Rech Scient Polypeptides derives des arn polymerases, et leurs utilisations
US6520949B2 (en) 2001-04-02 2003-02-18 Martin St. Germain Method and apparatus for administering fluid to animals subcutaneously
DE10119005A1 (de) 2001-04-18 2002-10-24 Roche Diagnostics Gmbh Verfahren zur Proteinexpression ausgehend von stabilisierter linearer kurzer DNA in zellfreien in vitro-Transkription/Translations-Systemen mit Exonuklease-haltigen Lysaten oder in einem zellulären System enthaltend Exonukleasen
US20030171253A1 (en) 2001-04-19 2003-09-11 Averil Ma Methods and compositions relating to modulation of A20
DE50201240D1 (de) 2001-04-23 2004-11-11 Amaxa Gmbh Pufferlössung für die elektroporation und verfahren umfassend die verwendung derselben
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6777187B2 (en) 2001-05-02 2004-08-17 Rubicon Genomics, Inc. Genome walking by selective amplification of nick-translate DNA library and amplification from complex mixtures of templates
US6527216B2 (en) 2001-05-08 2003-03-04 Magnatech International Llp Electronic length control wire pay-off system and method
US20050137155A1 (en) 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US8137911B2 (en) 2001-05-22 2012-03-20 Cellscript, Inc. Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
JP4323949B2 (ja) 2001-05-30 2009-09-02 ザ・スクリプス・リサーチ・インステイチユート 核酸用送達系
ES2240745T3 (es) 2001-06-05 2005-10-16 Curevac Gmbh Composicion farmaceutica que contiene un arnm estabilizado y optimizado para la traduccion, adecuada como vacuna y como regenerante de tejidos.
WO2002102839A2 (en) 2001-06-18 2002-12-27 Novartis Ag Novel g-protein coupled receptors and dna sequences thereof
US7547551B2 (en) 2001-06-21 2009-06-16 University Of Antwerp. Transfection of eukaryontic cells with linear polynucleotides by electroporation
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
AU2002352554A1 (en) 2001-06-26 2003-03-03 Novartis Ag G protein coupled receptors and dna sequences thereof
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2003029401A2 (en) 2001-07-13 2003-04-10 Advanced Research And Technology Institute Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
JP2004536614A (ja) 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ Ｐｄｅ３環状ヌクレオチド・ホスホジエステラーゼのアイソフォーム選択的な阻害剤および活性化剤
US20050106659A1 (en) 2001-08-27 2005-05-19 Klemens Kaupmann Novel g-protein coupled receptor and dna sequences thereof
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
DE10148886A1 (de) 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7384739B2 (en) 2001-11-14 2008-06-10 Toyo Boseki Kabushiki Kaisha Compositions for enhancing DNA synthesis, DNA polymerase-related factors and utilization thereof
AU2002361642A1 (en) 2001-11-16 2003-06-10 The University Of Tennessee Research Corporation Recombinant antibody fusion proteins and methods for detection of apoptotic cells
US20050032062A1 (en) 2001-11-29 2005-02-10 Salah-Dine Chibout Methods for the assessment and prognosis of sarcoidosis
CA2409775C (en) 2001-12-03 2010-07-13 F. Hoffmann-La Roche Ag Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro
AU2002368276A1 (en) 2001-12-07 2004-05-13 Chiron Corporation Endogenous retrovirus up-regulated in prostate cancer
EP1521594B1 (de) 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Mit onkogener transformation in verbindung gebrachte endogene retroviruspolypeptide
US20060275747A1 (en) 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
WO2003051923A2 (en) 2001-12-17 2003-06-26 Novartis Ag Novel g-protein coupled receptors and dna sequences thereof
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DK1474109T3 (da) 2001-12-21 2010-10-25 Alcon Inc Anvendelse af syntetiske uorganiske nanopartikler som bærere af ophthalmiske lægemidler
WO2003059381A2 (en) 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
FR2835749B1 (fr) 2002-02-08 2006-04-14 Inst Nat Sante Rech Med Composition pharmaceutique ameliorant le transfert de gene in vivo
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US7354742B2 (en) 2002-02-22 2008-04-08 Ortho-Mcneil Pharmaceutical, Inc. Method for generating amplified RNA
AU2003267943C1 (en) 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
AU2003213687A1 (en) 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
JP4679822B2 (ja) 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
JP4846200B2 (ja) 2002-04-04 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 免疫賦活性ｇ、ｕ含有オリゴリボヌクレオチド
EP1497327A2 (de) 2002-04-17 2005-01-19 Novartis AG Verfahren zur identifizierung von inhibitoren der bindung von are-enthaltenden mrnas an ein hur protein
GB0209539D0 (en) 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
EP1361277A1 (de) 2002-04-30 2003-11-12 Centre National De La Recherche Scientifique (Cnrs) Optimierung von Transgenexpression in Säugetierzellen
WO2003092623A2 (en) 2002-05-02 2003-11-13 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
US7374930B2 (en) 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US20040018525A1 (en) 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
DE10224200C1 (de) 2002-05-31 2003-08-21 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
US7198899B2 (en) 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
EP1519714B1 (de) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Verfahren und vorrichtung zur herstellung von liposomen
PL374580A1 (en) 2002-07-01 2005-10-31 The Kenneth S.Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2004007678A2 (en) 2002-07-16 2004-01-22 Advisys, Inc. Codon optimized synthetic plasmids
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP1393745A1 (de) 2002-07-29 2004-03-03 Hybridon, Inc. Modulierung der immunstimulierenden Eigenschaften von Oligonukleotiden und Analoga durch optimale Darstellung der 5'-Enden
EP1386925A1 (de) 2002-07-31 2004-02-04 Girindus AG Verfahren zur Herstellung von Oligonukleotiden
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
EP1873180B1 (de) 2002-08-14 2014-05-07 Novartis AG Ophthalmische Vorrichtung aus einem strahlungshärtbaren Präpolymer
AU2003278764C1 (en) 2002-09-06 2010-09-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
ATE412684T1 (de) 2002-09-09 2008-11-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen
US7534872B2 (en) 2002-09-27 2009-05-19 Syngen, Inc. Compositions and methods for the use of FMOC derivatives in DNA/RNA synthesis
LT3284753T (lt) 2002-10-17 2020-06-10 Genmab A/S Žmogaus monokloniniai antikūnai prieš cd20, skirti naudoti gydant išsėtinę sklerozę
DE60335490D1 (de) 2002-10-22 2011-02-03 Eisai R&D Man Co Ltd Spezifisch in postmitotischen dopamin-produzierenden neuronalen vorläuferzellen exprimiertes gen
AU2003294447A1 (en) 2002-11-21 2004-06-18 Epicentre Technologies Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
US7491234B2 (en) 2002-12-03 2009-02-17 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
US7625872B2 (en) 2002-12-23 2009-12-01 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
US7169892B2 (en) 2003-01-10 2007-01-30 Astellas Pharma Inc. Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
US20080227085A1 (en) 2003-01-17 2008-09-18 Pellegrini Matthew C Methods and Systems for the Identification of Rna Regulatory Sequences and Compounds that Modulate their Function
CA2514184C (en) 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7320961B2 (en) 2003-03-24 2008-01-22 Abbott Laboratories Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
EP1616033B1 (de) 2003-03-25 2010-03-03 Stratagene California Dna-polymerasefusionen und deren verwendungen
CA2522213A1 (en) 2003-04-08 2004-10-28 Dante J. Marciani Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
WO2004091657A2 (en) 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1620140B1 (de) 2003-05-05 2013-10-09 Ben-Gurion University Of The Negev Research And Development Authority Injizierbare vernetzte polymere zusammensetzungen und deren verwendungen
US20050147618A1 (en) 2003-05-06 2005-07-07 Rivera Daniel S. Clotting factor-Fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9567591B2 (en) 2003-05-15 2017-02-14 Mello Biotechnology, Inc. Generation of human embryonic stem-like cells using intronic RNA
GB0313132D0 (en) 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
EP1636385A4 (de) 2003-06-24 2010-06-02 Mirus Bio Corp Hemmung der genfunktion durch abgabe von genexpressionshemmern auf basis von polynucleotid an saugetierzellen in vivo
GB0316089D0 (en) 2003-07-09 2003-08-13 Xo Bioscience Ltd Differentiation method
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7575572B2 (en) 2003-07-15 2009-08-18 Spinal Generations, Llc Method and device for delivering medicine to bone
US20050013870A1 (en) 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US7135010B2 (en) 2003-09-30 2006-11-14 Damage Control Surgical Technologies, Inc. Method and apparatus for rapid deployment chest drainage
MXPA06003828A (es) 2003-10-06 2006-06-14 Novartis Ag Uso de polimorfismos geneticos que se asocian con la eficacia del tratamiento de enfermedad inflamatoria.
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050130201A1 (en) 2003-10-14 2005-06-16 Dharmacon, Inc. Splint-assisted enzymatic synthesis of polyribounucleotides
HUE031632T2 (en) 2003-11-05 2017-07-28 Roche Glycart Ag Antigen binding molecules with enhanced Fc receptor binding affinity and effector function
WO2005047536A2 (en) 2003-11-13 2005-05-26 Novartis Ag Detection of genomic amplification and deletion in cancer
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
US7699852B2 (en) 2003-11-19 2010-04-20 Zimmer Spine, Inc. Fenestrated bone tap and method
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
US8304183B2 (en) 2005-11-30 2012-11-06 Cellscript, Inc. Selective terminal tagging of nucleic acids
EP1691746B1 (de) 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mukoadhäsive arzneimittelabgabevorrichtungen und verfahren zu ihrer herstellung und verwendung
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
CN104013957B (zh) 2003-12-23 2016-06-29 泰勒公司 用新的抗il13单克隆抗体治疗癌症
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ATE440949T1 (de) 2004-01-30 2009-09-15 Maxygen Holdings Ltd Gesteuertes überlesen von stopcodons
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
EP2316857A1 (de) 2004-02-12 2011-05-04 Morphotek, Inc. Monoklonaler Antikörper spezifisch für Folatrezeptor alpha
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP3269738A1 (de) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypen des humanisiertem antikörper gegen interleukin-6-rezeptor
WO2005098433A2 (en) 2004-04-01 2005-10-20 Novartis Ag Diagnostic assays for alzheimer’s disease
EP1740946B1 (de) 2004-04-20 2013-11-06 Genmab A/S Humane monoklonale antikörper gegen cd20
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
WO2005108411A2 (en) 2004-05-05 2005-11-17 Isis Pharmaceuticals, Inc. Substituted pixyl protecting groups for oligonucleotide synthesis
JP2007537284A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド 核酸マイクロスフェア、その生成および送達
US8012747B2 (en) 2004-06-01 2011-09-06 San Diego State University Foundation Expression system
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JP2008502739A (ja) 2004-06-11 2008-01-31 トラスティーズ オブ タフツ カレッジ 絹に基づく薬物送達システム
WO2006046978A2 (en) 2004-06-28 2006-05-04 Argos Therapeutics, Inc. Cationic peptide-mediated transformation
MXPA06015234A (es) 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
AU2005328382C1 (en) 2004-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US7603349B1 (en) 2004-07-29 2009-10-13 Yahoo! Inc. User interfaces for search systems using in-line contextual queries
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7291208B2 (en) 2004-08-13 2007-11-06 Gore Enterprise Holdings, Inc. Grooved active and passive adsorbent filters
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
DK2386640T3 (en) 2004-08-26 2015-04-27 Engeneic Molecular Delivery Pty Ltd The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US7501486B2 (en) 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP1811018A4 (de) 2004-10-12 2007-11-28 Tissue Targeting Japan Inc Gehirnveranlagte markvorläuferzelle
EP2301536B1 (de) 2004-10-13 2014-04-09 PTC Therapeutics, Inc. Verbindungen zur Nonsense-Unterdrückung und Verfahren zu deren Verwendung
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
JP2008520740A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド Ｖｅｇｆ産生を阻害する活性因子としての置換されたフェノール
US7838657B2 (en) * 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US8354476B2 (en) 2004-12-10 2013-01-15 Kala Pharmaceuticals, Inc. Functionalized poly(ether-anhydride) block copolymers
WO2006071903A2 (en) 2004-12-28 2006-07-06 Ptc Therapeutics, Inc. Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions
US8535702B2 (en) 2005-02-01 2013-09-17 Boston Scientific Scimed, Inc. Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
EP2287608B1 (de) 2005-03-11 2014-01-08 Firalis SAS Biomarker für durch cox-2 inhibierende Substanzen verursachte kardiovaskuläre Nebenwirkungen
US8415325B2 (en) 2005-03-31 2013-04-09 University Of Delaware Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels
EP2062591A1 (de) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung
EP1910557A2 (de) 2005-04-07 2008-04-16 Chiron Corporation Gene in verbindung mit krebs
EP1885403B1 (de) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethylenglykol)-Konjugate von Lysostaphin
EP1899467A2 (de) 2005-04-26 2008-03-19 Coley Pharmaceutical GmbH Modifizierte oligoribonukleotidanaloge mit verbesserter immunstimulierender aktivität
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
US20060265771A1 (en) 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
MX2007015107A (es) 2005-06-03 2008-02-15 Genentech Inc Metodo para producir anticuerpos con funcion mejorada.
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
KR101304157B1 (ko) 2005-06-16 2013-09-06 넥타르 테라퓨틱스 분해가능한 결합을 갖는 컨주게이트 및 이러한 컨주게이트제조에 유용한 고분자 시약
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
AU2006282042B2 (en) 2005-06-17 2011-12-22 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
CN101495504A (zh) 2005-06-30 2009-07-29 阿切埃米克斯有限公司 用于生产全2’-修饰的核酸转录产物的材料和方法
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US20080220471A1 (en) 2005-07-27 2008-09-11 Genentech, Inc. Vectors and Methods Using Same
EP4174179A3 (de) 2005-08-23 2023-09-27 The Trustees of the University of Pennsylvania Rna-haltige modifizierte nukleoside und verfahren zur verwendung davon
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
US20070048741A1 (en) 2005-08-24 2007-03-01 Getts Robert C Methods and kits for sense RNA synthesis
US8715677B2 (en) 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
US8420605B2 (en) 2005-09-07 2013-04-16 The University Of Strathclyde Hydrogel compositions
US20120021042A1 (en) 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US20070105124A1 (en) 2005-11-08 2007-05-10 Getts Robert C Methods and kits for nucleic acid amplification
AU2006314757A1 (en) 2005-11-18 2007-05-24 Bioline Limited A method for enhancing enzymatic DNA polymerase reactions
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
EP1969000A2 (de) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Zellenpenetrierende peptide zur intrazellulären weiterleitung von molekülen
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1960547A2 (de) 2005-12-08 2008-08-27 Novartis AG Auswirkungen von fgfr3-inhibitoren auf die gentranskription
NZ569530A (en) 2005-12-13 2011-07-29 Univ Kyoto Nuclear reprogramming factor
CA2633063A1 (en) 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
WO2007087178A2 (en) 2006-01-13 2007-08-02 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
US20070178103A1 (en) 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
CN101420984B (zh) 2006-02-21 2013-01-02 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
US8431160B2 (en) 2006-02-24 2013-04-30 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
WO2007100789A2 (en) 2006-02-24 2007-09-07 Wyeth Gpat3 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase
EP3620469A1 (de) 2006-02-28 2020-03-11 Biogen MA Inc. Verfahren zur behandlung von entzündungs- und autoimmunerkrankungen mit natalizumab
US7910152B2 (en) 2006-02-28 2011-03-22 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
EP2012751A4 (de) 2006-03-21 2010-11-24 Morehouse School Of Medicine Neue nanopartikel zur wirkstofffreisetzung
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
CA2648291A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
EP1852127A1 (de) 2006-05-02 2007-11-07 Charité - Universitätsmedizin Berlin Verwendung eines B-Zell entfernenden Antikörpers zur Behandlung von Polyoma Virusinfektionen
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
CN104356230A (zh) 2006-06-02 2015-02-18 哈佛大学校长及研究员协会 蛋白质表面重建
JP5605895B2 (ja) 2006-07-04 2014-10-15 ゲンマブ エー／エス Ｃｏｐｄを処置するためのｃｄ２０結合分子
EP2397123A1 (de) 2006-07-07 2011-12-21 Aarhus Universitet Nanopartikel zur Nukleinsäurelieferung
PT2038310E (pt) 2006-07-12 2010-08-25 Novartis Ag Copolímeros reticuláveis por via actínica para o fabrico de lentes de contacto
US20110097261A1 (en) 2006-07-20 2011-04-28 Janatpour Mary J Amigo-2-inhibitors for treating, diagnosing or detecting cancer
EP2054036B1 (de) 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Feste nanoteilchenförmige formulierung von wasserunlöslichen pharmazeutischen substanzen mit verringerter ostwald-reifung
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
JP2010507567A (ja) 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
WO2008022046A2 (en) 2006-08-18 2008-02-21 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics
US8658211B2 (en) 2006-08-18 2014-02-25 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
US7846895B2 (en) 2006-09-06 2010-12-07 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
ATE498393T1 (de) 2006-09-08 2011-03-15 Univ Johns Hopkins Zusammensetzungen zur transportintensivierung durch die schleimhaut
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
GB0619182D0 (en) 2006-09-29 2006-11-08 Leuven K U Res & Dev Oligonucleotide arrays
CA2665225C (en) 2006-10-03 2015-06-30 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
AU2007333528B2 (en) 2006-10-05 2013-10-17 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US7999087B2 (en) 2006-11-15 2011-08-16 Agilent Technologies, Inc. 2′-silyl containing thiocarbonate protecting groups for RNA synthesis
US8242258B2 (en) 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US7893227B2 (en) 2006-12-05 2011-02-22 Lasergen, Inc. 3′-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9034348B2 (en) 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
CN105582521A (zh) 2006-12-18 2016-05-18 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
WO2008082563A2 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
WO2008140615A2 (en) 2006-12-21 2008-11-20 Novozymes, Inc. Modified messenger rna stabilizing sequences for expressing genes in bacterial cells
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
CA2673029C (en) 2006-12-22 2017-03-28 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US8338166B2 (en) 2007-01-04 2012-12-25 Lawrence Livermore National Security, Llc Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
JP4866467B2 (ja) 2007-01-30 2012-02-01 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
US8859229B2 (en) 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
WO2008096370A2 (en) 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
US8333799B2 (en) 2007-02-12 2012-12-18 C. R. Bard, Inc. Highly flexible stent and method of manufacture
US8242087B2 (en) 2007-02-27 2012-08-14 K.U.Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
EP1964922A1 (de) 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Verbesserung der Herstellung von Proteinen
AR065573A1 (es) 2007-03-02 2009-06-17 Boehringer Ingelheim Int Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.
AU2008222822A1 (en) 2007-03-05 2008-09-12 Washington University Nanoparticle delivery systems for membrane-integrating peptides
EP2125892A2 (de) 2007-03-20 2009-12-02 Millennium Pharmaceuticals, Inc. Für a4b7 integrin-bindendes humanisiertes immunglobulin kodierende nukleinsäuren
WO2014064687A1 (en) 2012-10-22 2014-05-01 Deliversir Ltd A system for delivering therapeutic agents into living cells and cells nuclei
RU2435616C2 (ru) 2007-04-27 2011-12-10 Эко Терапьютикс, Инк. Устройство для повышения проницаемости кожи для обнаружения аналита или трансдермальтной доставки лекарственных препаратов
EP2777710A1 (de) 2007-04-30 2014-09-17 Glaxosmithkline LLC Verfahren zur Verabreichung von Anti-IL-5-Antikörpern
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
DK2494993T3 (en) 2007-05-04 2018-11-12 Marina Biotech Inc Amino acid lipids and uses thereof
US7682789B2 (en) 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
US8728491B2 (en) 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
WO2008141248A2 (en) 2007-05-10 2008-11-20 Agilent Technologies, Inc. Thiocarbon-protecting groups for rna synthesis
PT3072525T (pt) 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
WO2008144365A2 (en) 2007-05-17 2008-11-27 Novartis Ag Method for making dry powder compositions containing ds-rna based on supercritical fluid technology
EA200901550A1 (ru) 2007-05-22 2010-10-29 Новартис Аг Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
WO2008151058A2 (en) 2007-05-30 2008-12-11 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
DK2826863T3 (en) 2007-05-30 2017-12-04 Univ Northwestern NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
PL2167523T3 (pl) 2007-06-19 2014-12-31 Univ Louisiana State Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA
EP2173872B1 (de) 2007-06-29 2014-04-02 CellScript, Inc. Copy-dna und sense-rna
US8367318B2 (en) 2007-07-23 2013-02-05 Dharmacon, Inc. Screening of micro-RNA cluster inhibitor pools
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
WO2009024599A1 (en) 2007-08-23 2009-02-26 Novartis Ag Methods for detecting oligonucleotides
WO2009030368A1 (en) 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Combination therapy with type i and type ii anti-cd20 antibodies
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
US8506928B2 (en) 2007-09-07 2013-08-13 The Regents Of The University Of California Methods and compounds for targeting tissues
WO2009042892A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
US8835621B2 (en) 2007-09-26 2014-09-16 Intrexon Corporation Synthetic 5'UTRs, expression vectors, and methods for increasing transgene expression
SI2644594T1 (sl) 2007-09-28 2017-10-30 Pfizer Inc. Ciljanje rakavih celic z uporabo nanodelcev
EP2042193A1 (de) 2007-09-28 2009-04-01 Biomay AG RNA-Impfstoffe
US8470560B2 (en) 2007-10-03 2013-06-25 The United States Of America As Represented By The Secretary Of The Army CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
CA2917512A1 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2205277B1 (de) 2007-10-22 2017-07-26 Genmab A/S Neuartige antikörpertherapien
RU2531493C2 (ru) 2007-11-01 2014-10-20 Юниверсити Оф Рочестер Рекомбинантный фактор viii, обладающий повышенной стабильностью
CA2705263A1 (en) 2007-11-09 2009-05-14 Novartis Ag Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies
WO2009062348A1 (fr) 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Procédés d'inhibition d'une infection par le virus de la grippe et leurs médicaments
CN101932608A (zh) 2007-11-30 2010-12-29 葛兰素集团有限公司 抗原结合构建体
US7871985B2 (en) 2007-12-10 2011-01-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor VII gene
CA2708766C (en) 2007-12-11 2016-02-02 The Scripps Research Institute Compositions and methods related to mrna translational enhancer elements
EP2229459B1 (de) 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Vorbeugung oder Behandlung einer RSV-Infektion
EP2072618A1 (de) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Verwendung von RNA zur Neuprogrammierung von Körperzellen
BRPI0819593A2 (pt) 2007-12-21 2015-05-05 Genentech Inc "método para tratamento de um paciente com artrite reumatóide (ra)"
KR20100120663A (ko) 2008-01-23 2010-11-16 아지노모토 가부시키가이샤 Ｌ-아미노산의 제조법
WO2009093384A1 (ja) 2008-01-24 2009-07-30 National Institute Of Advanced Industrial Science And Technology ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法
EP2548960B1 (de) 2008-01-31 2018-01-31 CureVac AG Nukleinsäure der Formel (NuGIXmGnNv)a und Derivate davon als immunstimulierendes Mittel/Adjuvans
US20100330677A1 (en) 2008-02-11 2010-12-30 Cambridge Enterprise Limited Improved Reprogramming of Mammalian Cells, and Cells Obtained
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
DE102008009920A1 (de) 2008-02-15 2009-08-20 Aj Innuscreen Gmbh Mobiles Gerät für die Nukleinsäureisolierung
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
US20120027813A1 (en) 2008-02-22 2012-02-02 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines for pediatric use
WO2009108891A2 (en) 2008-02-29 2009-09-03 Egen, Inc. Modified poloxamers for gene expression and associated methods
CN102027043A (zh) 2008-03-14 2011-04-20 艾根股份有限公司 生物可降解的交联支链聚(亚烷基亚胺)
ES2759075T3 (es) 2008-03-14 2020-05-07 Biocon Ltd Un anticuerpo monoclonal y un método del mismo
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
AU2009238607B2 (en) 2008-04-25 2015-08-06 Northwestern University Nanostructures suitable for sequestering cholesterol
AU2009243187C1 (en) 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration
AU2009241354B2 (en) 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
US9394538B2 (en) 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines
EP2891501B1 (de) 2008-05-08 2016-09-21 MiniPumps, LLC Verfahren zur Herstellung von Arzneimittelausgabepumpen
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
AU2009246327B8 (en) 2008-05-13 2013-10-03 Phaserx, Inc. Diblock copolymers and polynucleotide complexes thereof for delivery into cells
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
FR2931824B1 (fr) 2008-05-29 2014-11-28 Centre Nat Rech Scient Procede de synthese d'arn par voie chimique.
CN102186879A (zh) 2008-05-29 2011-09-14 韩诺生物制约株式会社 修饰的显示增加的蛋白酶抗性的促红细胞生成素(epo)多肽及其药物组合物
US20100086922A1 (en) 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
SI2285350T1 (en) 2008-06-16 2018-03-30 Pfizer Inc. Methods for the preparation of diblock copolymers functionalized with targeting agent for use in the manufacture of therapeutic nanoparticles
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
JP6363320B2 (ja) 2008-06-16 2018-07-25 ファイザー・インク 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
WO2010009065A2 (en) 2008-07-15 2010-01-21 Novartis Ag Amphipathic peptide compositions
CA2730737A1 (en) 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
CA2731760C (en) * 2008-07-24 2019-09-24 Meiji Seika Kaisha, Ltd. Pyripyropene a biosynthetic gene
EP2331561A4 (de) 2008-09-03 2013-02-27 Xenome Ltd Peptidkonjugatbibliotheken und herstellungsverfahren dafür
CA2738635C (en) 2008-09-05 2019-12-31 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2010027512A2 (en) 2008-09-06 2010-03-11 Chemgenes Corporation Rna synthesis - phosphoramidites for synthetic rna in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic rna at the 3' - end
US20120100558A1 (en) 2008-09-08 2012-04-26 Hanash Samir M Lung cancer diagnosis
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010042490A1 (en) 2008-10-06 2010-04-15 Boston Medical Center Corporation A single lentiviral vector system for induced pluripotent (ips) stem cells derivation
ES2475065T3 (es) 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010047765A2 (en) 2008-10-20 2010-04-29 Massachussetts Institute Of Technology Nanostructures for drug delivery
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR102459839B1 (ko) 2008-11-10 2022-10-27 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
EP2191840A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Melphalan erkennen
US8324368B2 (en) 2008-12-10 2012-12-04 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
EP2196476A1 (de) 2008-12-10 2010-06-16 Novartis Ag Antikörperformulierung
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
EP2376091A4 (de) 2008-12-12 2012-08-01 Univ California Neue targets zur behandlung von hypercholesterinmie
EP2379064B1 (de) 2008-12-15 2020-02-26 Pfizer Inc. Lange zirkulierende nanoteilchen zur verzögerten freisetzung von therapeutischen mitteln
KR20110111303A (ko) 2009-01-16 2011-10-10 글락소스미스클라인 엘엘씨 벤다무스틴 및 항-ｃｄ２０ 항체의 조합을 이용한 암의 치료
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
EP3243504A1 (de) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Verbesserte lipidformulierung
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20140141089A1 (en) 2009-02-11 2014-05-22 Colorado School Of Mines Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same
JP5735927B2 (ja) 2009-02-24 2015-06-17 ザ スクリプス リサーチ インスティテュート タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
WO2010105277A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
ES2931174T3 (es) 2009-03-20 2022-12-27 Egen Inc Derivados de poliamina
WO2010111290A1 (en) 2009-03-23 2010-09-30 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
DK2414387T3 (en) 2009-04-03 2016-03-07 Univ Chicago Compositions and methods related to the Protein A (spa) variants
WO2010120266A1 (en) 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
JP2013525260A (ja) 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 急性骨髄性白血病を治療するための組成物および方法
US20100273220A1 (en) 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
AR076402A1 (es) 2009-04-27 2011-06-08 Novartis Ag Composiciones y metodos para aumentar el crecimiento muscular
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
US8715736B2 (en) 2009-04-30 2014-05-06 Florida Agricultural And Mechanical University Nanoparticle formulations for skin delivery
KR20210031549A (ko) 2009-05-05 2021-03-19 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
DE202009007116U1 (de) 2009-05-18 2010-10-14 Amoena Medizin-Orthopädie-Technik GmbH Antidekubituskissen
US8574835B2 (en) 2009-05-29 2013-11-05 Life Technologies Corporation Scaffolded nucleic acid polymer particles and methods of making and using
EP2440556A1 (de) 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Phosphatidylinositol 3-kinasehemmer
SI3431076T1 (sl) 2009-06-10 2022-04-29 Arbutus Biopharma Corporation Izboljšana lipidna formulacija
CA2764832A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Lipid formulated dsrna targeting the pcsk9 gene
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, preparations containing them and their uses
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
DE102009033507A1 (de) * 2009-07-15 2011-01-20 Niro-Plan Ag Vorrichtung und Verfahren zum Erzeugen von gekühltem Kaffee
EP2459231B1 (de) * 2009-07-31 2016-06-08 Ethris Gmbh Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
EP2281579A1 (de) 2009-08-05 2011-02-09 BioNTech AG Impfstoffzusammensetzung mit 5'-Cap-modifizierter RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
US8859284B2 (en) 2009-10-22 2014-10-14 The United States Of America, As Represented By The Secretary Of The Navy Delivery of nanoparticles to neurons
US8449916B1 (en) 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
WO2011060250A1 (en) 2009-11-13 2011-05-19 Bend Research, Inc. Cationic dextran polymer derivatives
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
TR201901311T4 (tr) 2009-12-01 2019-02-21 Translate Bio Inc İnsan genetik hastalıklarında mRNA'nın teslimi için steroid türevi.
US20110245756A1 (en) 2009-12-03 2011-10-06 Rishi Arora Devices for material delivery, electroporation, sonoporation, and/or monitoring electrophysiological activity
EA025416B1 (ru) 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
LT3287525T (lt) 2009-12-07 2020-02-10 The Trustees Of The University Of Pennsylvania Rnr preparatai, apimantys išgrynintą modifikuotą rnr, skirti ląstelių reprogramavimui
US20130189741A1 (en) 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
WO2011069528A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2512522A4 (de) 2009-12-16 2013-09-25 Brigham & Womens Hospital Partikel zur abgabe mehrerer wirkstoffe
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
NZ600725A (en) 2009-12-18 2015-08-28 Univ British Colombia Methods and compositions for delivery of nucleic acids
CA2785492C (en) 2009-12-23 2018-07-24 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
CN102869774B (zh) 2010-02-24 2018-02-09 箭头研究公司 用于靶向递送siRNA的组合物
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20130133483A1 (en) 2010-03-08 2013-05-30 University Of Rochester Synthesis of Nanoparticles Using Reducing Gases
KR20130006663A (ko) 2010-03-16 2013-01-17 유니버시티 오브 유타 리서치 파운데이션 뉴클레오티드 전달을 높이기 위한 환원가능한 폴리(아미도 에틸렌이민)으로의 절단성 변형법
WO2011116072A1 (en) 2010-03-16 2011-09-22 Escape Therapeutics, Inc. Hybrid hydrogel scaffold compositions and methods of use
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
JP2013521994A (ja) 2010-03-24 2013-06-13 ユナイテッド ステイツ エンドスコピー グループ，インコーポレイテッド マルチプル生体検査装置
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
CA2794307A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110247090A1 (en) 2010-04-02 2011-10-06 Intrexon Corporation Synthetic 5'UTRs, Expression Vectors, and Methods for Increasing Transgene Expression
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
WO2011125469A1 (ja) 2010-04-09 2011-10-13 国立大学法人東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
WO2011127456A2 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
KR101196667B1 (ko) 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
EP3540059A1 (de) 2010-04-16 2019-09-18 Nuevolution A/S Bifunktionelle komplexe und verfahren zur herstellung sowie verwendung derartiger komplexe
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP2377938A1 (de) 2010-04-16 2011-10-19 Eukarys Capping-anfällige RNA-Polymeraseenzyme und deren Anwendungen
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
AU2011311255B2 (en) 2010-04-28 2015-10-08 Sorrento Therapeutics, Inc. Method for increasing permeability of an epithelial barrier
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
MA34263B1 (fr) 2010-04-30 2013-05-02 Novartis Ag Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
EP2387999A1 (de) 2010-05-21 2011-11-23 CureVac GmbH Histidin enthaltende Lösung zur Transfektion und/oder Injektion von Nukleinsäuren und deren Verwendungen
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
JP5957646B2 (ja) 2010-06-04 2016-07-27 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． オリゴヌクレオチド送達のための新規な低分子量カチオン性脂質
WO2011157713A2 (en) 2010-06-14 2011-12-22 F. Hoffmann-La Roche Ag Cell-penetrating peptides and uses therof
WO2011163121A1 (en) 2010-06-21 2011-12-29 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
EP2589391B1 (de) 2010-07-01 2018-11-14 Rosetta Exosome Co., Ltd. Mikrovesikeln aus bakterienzellen zur verwendung bei der behandlung von krebs
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
MX2013000164A (es) 2010-07-06 2013-03-05 Novartis Ag Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
JP6061849B2 (ja) 2010-07-06 2017-01-18 ノバルティス アーゲー 自己複製ｒｎａ分子についてのビリオン様送達粒子
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
EP2590625B1 (de) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Kationische öl-in-wasser emulsionen
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
KR20220097518A (ko) 2010-07-09 2022-07-07 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US20130177523A1 (en) 2010-07-13 2013-07-11 University Of Utah Research Foundation Gold particles and methods of making and using the same in cancer treatment
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
WO2012021516A2 (en) 2010-08-09 2012-02-16 The Trustees Of The University Of Pennsylvania Nanoparticle-oligonucletide hybrid structures and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
CN103080313A (zh) 2010-08-20 2013-05-01 天蓝制药公司 缀合物、粒子、组合物以及相关方法
EP2605816B1 (de) 2010-08-20 2019-01-23 University Of Washington Umlaufende aerosolvorrichtung zur abgabe von arzneimitteln an die riechschleimhaut und das gehirn
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
RS63984B1 (sr) 2010-08-31 2023-03-31 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
CA2809851A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
KR20130100278A (ko) 2010-08-31 2013-09-10 머크 샤프 앤드 돔 코포레이션 올리고뉴클레오티드의 전달을 위한 신규 단일 화학 존재물 및 방법
AU2011295938B2 (en) 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
EP3556396B1 (de) 2010-08-31 2022-04-20 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012034077A2 (en) 2010-09-09 2012-03-15 The University Of Chicago Compositions and methods related to attenuated staphylococcal strains
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9669097B2 (en) 2010-09-20 2017-06-06 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP2619307A1 (de) 2010-09-21 2013-07-31 RiboxX GmbH Verfahren zur synthese von rna mittels dna-templat
US20130280334A1 (en) 2010-09-24 2013-10-24 Massachusetts Institute Of Technology Nanostructured Gels Capable of Controlled Release of Encapsulated Agents
WO2012050975A2 (en) 2010-09-29 2012-04-19 The University Of North Carolina At Chapel Hill Novel circular mammalian rna molecules and uses thereof
JP2013545723A (ja) 2010-09-30 2013-12-26 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチドの送達のための低分子量カチオン性脂質
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
US10078075B2 (en) 2011-12-09 2018-09-18 Vanderbilt University Integrated organ-on-chip systems and applications of the same
EP2629802B1 (de) 2010-10-21 2019-12-04 Sirna Therapeutics, Inc. Kationische lipide mit geringem molekulargewicht zur oligonukleotidabgabe
US9198964B2 (en) 2010-10-29 2015-12-01 Merck Sharp & Dohme Corp. Recombinant subunit dengue virus vaccine
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
EP2638162B1 (de) 2010-11-09 2016-08-10 The Regents of The University of California Hautdurchdringende und in zellen eindringende peptide sowie verfahren zu ihrer verwendung
CN106434676B (zh) 2010-11-12 2020-10-23 宾夕法尼亚大学托管会 共有前列腺抗原、编码所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途
CN105327363A (zh) 2010-11-16 2016-02-17 塞莱克塔生物科学股份有限公司 免疫刺激性寡核苷酸
DK2640842T3 (en) 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
EP3213770B1 (de) 2010-11-19 2021-02-24 Idera Pharmaceuticals, Inc. Verbindungen mit immunregulatorischem oligonukleotid (iro) zur modulation von immunreaktionen auf basis von toll-like-rezeptoren
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012072096A1 (en) 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
WO2012103985A2 (en) 2010-12-16 2012-08-09 Steve Pascolo Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2012088381A2 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
KR20130108655A (ko) 2010-12-29 2013-10-04 에프. 호프만-라 로슈 아게 핵산의 세포내 전달을 위한 소분자 접합체
EP2661255B1 (de) 2011-01-04 2021-03-10 Brown University Nanoröhrchen als träger von nukleinsäuren in zellen
WO2012094574A2 (en) 2011-01-06 2012-07-12 The Johns Hopkins University Stabilized polyribonucleotide nanoparticles
US20140080766A1 (en) 2011-01-07 2014-03-20 Massachusetts Institute Of Technology Compositions and methods for macromolecular drug delivery
EP3202760B1 (de) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylierte lipide und deren verwendung zur wirkstofffreisetzung
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
CA2825023A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
US20140066363A1 (en) 2011-02-07 2014-03-06 Arun K. Bhunia Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
US20120207840A1 (en) 2011-02-10 2012-08-16 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer
CA2826904A1 (en) 2011-02-14 2012-08-23 Swift Biosciences, Inc. Polynucleotide primers and probes
CA2827118A1 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
WO2012112689A1 (en) 2011-02-15 2012-08-23 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
EP2489371A1 (de) 2011-02-18 2012-08-22 Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria Trägerpeptide zur Verabreichung von Arzneimitteln
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
CN103492574B (zh) 2011-02-22 2015-12-09 加州理工学院 使用腺相关病毒（aav）载体递送蛋白
US8696637B2 (en) 2011-02-28 2014-04-15 Kimberly-Clark Worldwide Transdermal patch containing microneedles
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2683812A4 (de) 2011-03-07 2014-12-03 Massachusetts Inst Technology Verfahren zur zelltransfektion mit nukleinsäuren
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
SG192962A1 (en) 2011-03-17 2013-09-30 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
US20140212503A1 (en) 2011-03-17 2014-07-31 Hyukjin Lee Delivery system
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolípidos
CN103476949A (zh) 2011-03-28 2013-12-25 诺瓦提斯公司 与细胞周期蛋白依赖性激酶抑制剂相关的标志物
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
AU2012236099A1 (en) * 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
EP2694524B1 (de) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services 2 '-o-aminooxymethylnukleosidderivate zur verwendung bei der synthese und modifizierung von nukleosiden, nukleotiden und oligonukleotiden
WO2012142132A1 (en) 2011-04-11 2012-10-18 Life Technologies Corporation Polymer particles and methods of making and using same
US11135174B2 (en) 2011-04-13 2021-10-05 The Trustees Of The University Of Pennsylvania Coated mesoporous nanoparticles
WO2013158127A1 (en) 2012-04-16 2013-10-24 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
US20140178894A1 (en) 2011-04-20 2014-06-26 Novartis Forschungsstiftung, Zweigniederlassung Culture medium suitable for the culture of undifferentiated cells
US20140287022A1 (en) 2011-04-26 2014-09-25 Molecular Express, Inc. Liposomal formulations
WO2012149536A1 (en) 2011-04-28 2012-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neutralizing antibodies to nipah and hendra virus
CN103687590A (zh) 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
CN107970440A (zh) 2011-04-29 2018-05-01 西莱克塔生物科技公司 致耐受性合成纳米载体
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN103826459B (zh) 2011-05-02 2017-05-10 韦恩州立大学 蛋白质诱导的多能细胞技术及其用途
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN103547350A (zh) 2011-05-10 2014-01-29 巴斯夫欧洲公司 水包油乳液
US9283279B2 (en) 2011-05-11 2016-03-15 Ramot At Tel-Aviv University Ltd. Targeted polymeric conjugates and uses thereof
CA2835492A1 (en) 2011-05-12 2012-11-15 Helmut Vockner Novel pharmaceutical formulation
CN104023708A (zh) 2011-05-12 2014-09-03 耶路撒冷希伯来大学依苏姆研究发展公司 包含聚合物缀合的脂质的脂质体和有关用途
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
CA2835428A1 (en) 2011-05-17 2012-11-22 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012162174A1 (en) 2011-05-20 2012-11-29 Kohler Co. Toilet installation system and method
JP2014516531A (ja) 2011-05-25 2014-07-17 ノバルティス アーゲー 肺癌に対するバイオマーカー
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
MX349011B (es) 2011-06-02 2017-07-05 Novartis Ag Biomarcadores para terapia de inhibidor de hedgehog.
EP2714017B1 (de) 2011-06-02 2018-08-01 The Regents of The University of California In membranen verkapselte nanopartikel und verwendungsverfahren dafür
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
EP3998064A1 (de) 2011-06-08 2022-05-18 Translate Bio, Inc. Spaltbare lipide
ES2911653T3 (es) 2011-06-08 2022-05-20 Translate Bio Inc Composiciones de nanopartículas lipídicas y métodos para el suministro de ARNm
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
US8916696B2 (en) 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CA2839196A1 (en) 2011-06-15 2012-12-20 Chrontech Pharma Ab Injection needle and device
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
US9862926B2 (en) 2011-06-27 2018-01-09 Cellscript, Llc. Inhibition of innate immune response
EP3797824A1 (de) 2011-06-28 2021-03-31 Inovio Pharmaceuticals, Inc. Minimal invasive dermale elektroporationsvorrichtung
JP6472999B2 (ja) 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
JP2014520506A (ja) 2011-07-04 2014-08-25 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 核酸複合体
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
EP2729126B1 (de) 2011-07-06 2020-12-23 GlaxoSmithKline Biologicals SA Liposomen mit nützlichem n:p-verhältnis zur freisetzung von rna-molekülen
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2013006834A1 (en) 2011-07-06 2013-01-10 Novartis Ag Oil-in-water emulsions that contain nucleic acids
EP3456316A1 (de) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Kationische öl-in-wasser-emulsionen
EP2729501A2 (de) 2011-07-07 2014-05-14 Life Technologies Corporation Polymerteilchen, nukleinsäurepolymerpartikel sowie verfahren zu ihrer herstellung und verwendung
US20130012566A1 (en) 2011-07-10 2013-01-10 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment of Alopecia
EP2758458A4 (de) 2011-07-10 2015-10-21 Harvard College Zusammensetzungen und verfahren zur selbstverfertigung von polymeren mit komplementären makroskopischen und mikroskopischen ablagerungseinheiten
WO2013009717A1 (en) 2011-07-10 2013-01-17 Elisabet De Los Pinos Virion derived protein nanoparticles for delivering diagnostic or therapeutic agents for the treatment of skin-related diseases
GB2492999A (en) 2011-07-20 2013-01-23 Univ Central Lancashire Neutron detector
US20140148503A1 (en) 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
CN103732211B (zh) 2011-07-21 2017-03-01 禾大国际股份公开有限公司 支化的聚醚‑聚酰胺嵌段共聚物及其制造与使用方法
EP2736921B1 (de) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Zusammensetzungen und verfahren zum testen der funktionellen immunogenität von parvovirus-impfstoffen
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
AU2012296576B2 (en) 2011-08-15 2017-09-07 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
CN104024328A (zh) 2011-08-26 2014-09-03 箭头研究公司 用于体内核酸递送的聚(乙烯基酯)聚合物
SI2750707T1 (sl) 2011-08-31 2019-02-28 Glaxosmithkline Biologicals Sa Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
EP2750712A2 (de) 2011-08-31 2014-07-09 Mallinckrodt LLC Nanopartikel-peg-modifizierung mit h-phosphonaten
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
JP2014525462A (ja) 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｄｇｆｒキナーゼ阻害剤としての化合物および組成物
JP2014525435A (ja) 2011-09-02 2014-09-29 ノバルティス アーゲー Ｈｓｆ１関連疾患を処置するための有機組成物
EP3384938A1 (de) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
EP2755683B1 (de) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Verfahren zur herstellung von saccharidprotein-glykokonjugaten
US20150017245A1 (en) 2011-09-22 2015-01-15 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
WO2013072929A2 (en) 2011-09-23 2013-05-23 Indian Institute Of Technology Nanop article based cosmetic composition
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
WO2013055971A1 (en) 2011-10-11 2013-04-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Polymers for delivering a substance into a cell
AU2012322704B2 (en) 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
WO2014066811A1 (en) 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
EP2766407B1 (de) 2011-10-12 2018-06-27 The Curators Of The University Of Missouri Pentablock-polymere
US20150272885A1 (en) 2011-10-14 2015-10-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
US9296826B2 (en) 2011-10-14 2016-03-29 Novartis Ag Antibodies and methods for WNT pathway-related diseases
WO2013059509A1 (en) 2011-10-18 2013-04-25 Micell Technologies, Inc. Drug delivery medical device
HUE057604T2 (hu) 2011-10-18 2022-06-28 Dicerna Pharmaceuticals Inc Amin-kationos lipidek és felhasználásuk
JP2014532620A (ja) 2011-10-20 2014-12-08 ノバルティス アーゲー 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン
EP2768507B1 (de) 2011-10-20 2019-12-11 Novartis AG Prädiktive biomarker des ansprechens auf eine behandlung mit dem nikotinischen acetylcholinrezeptor alpha-7
EP3915545A1 (de) 2011-10-25 2021-12-01 The University of British Columbia Lipidnanopartikel von begrenzter grösse und verfahren dafür
WO2013061290A1 (en) 2011-10-26 2013-05-02 Nanopass Technologies Ltd. Microneedle intradermal drug delivery device with auto-disable functionality
EP2771059B1 (de) 2011-10-27 2019-07-17 Sorrento Therapeutics, Inc. Transdermale freisetzung von hochviskosen bioaktiven wirkstoffen
KR102272498B1 (ko) 2011-10-27 2021-07-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US20140323907A1 (en) 2011-10-28 2014-10-30 Jason Frazier Methods for drug delivery
WO2013062140A1 (en) 2011-10-28 2013-05-02 Kyoto University Method for efficiently inducing differentiation of pluripotent stem cells into hepatic lineage cells
JP6143767B2 (ja) 2011-10-31 2017-06-07 マリンクロッド エルエルシー がん治療用組合せリポソーム組成物
ES2936387T3 (es) 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9872870B2 (en) 2011-11-04 2018-01-23 University Of Notre Dame Du Lac Multifunctional micellar nanoparticle-based drug and targeting agent system
SG11201401964TA (en) 2011-11-04 2014-05-29 Agency Science Tech & Res Self-assembled composite ultrasmall peptide-polymer hydrogels
EP2773669B1 (de) 2011-11-04 2018-03-28 Novartis AG Halbwertszeitverlängerer für ldl-verwandtes protein (6) lrp6
PL2773326T3 (pl) 2011-11-04 2019-06-28 Nitto Denko Corporation Sposób sterylnego wytwarzania cząstek lipid-kwas nukleinowy
US20130116408A1 (en) 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130115247A1 (en) 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
EP2776459A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Stäbchenzellenspezifischer promoter
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
WO2013070872A1 (en) 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
WO2013070653A1 (en) 2011-11-09 2013-05-16 Board Of Trustees Michigan State University Metallic nanoparticle synthesis with carbohydrate capping agent
CN107875382B (zh) 2011-11-11 2024-03-08 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
WO2013071047A1 (en) 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
CA2855826A1 (en) 2011-11-14 2013-05-23 Novartis Ag Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof
RU2014124184A (ru) 2011-11-15 2015-12-27 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
FI2790681T4 (fi) 2011-11-18 2023-05-04 Polymeerillä päällystettyjä proteiinimikrohiukkasia käsittävän pitkävaikutteisen farmaseuttisen formulaation valmistusmenetelmä käyttäen sumutuskuivausta
CA2856252A1 (en) 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
WO2013082111A2 (en) 2011-11-29 2013-06-06 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
CN104080506B (zh) 2011-11-30 2017-03-08 3M创新有限公司 包含肽治疗剂和氨基酸的微针装置以及制备和使用其的方法
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
WO2013082590A1 (en) 2011-12-02 2013-06-06 Invivo Therapeutics Corporation Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants
WO2013082470A1 (en) 2011-12-02 2013-06-06 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
US9814867B2 (en) 2011-12-05 2017-11-14 Nano Precision Medical, Inc. Device having titania nanotube membrane for drug delivery
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CA2858148C (en) 2011-12-05 2023-03-14 Factor Bioscience Inc. Methods and products for transfecting cells
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2788006A1 (de) 2011-12-07 2014-10-15 Alnylam Pharmaceuticals, Inc. Bioabbaubare lipide zur wirkstofffreisetzung
EP2787977A4 (de) 2011-12-09 2015-05-06 Univ California Liposomale wirkstoffverkapselung
WO2013086502A1 (en) 2011-12-09 2013-06-13 President And Fellows Of Harvard College Organ chips and uses thereof
WO2013086486A1 (en) 2011-12-09 2013-06-13 President And Fellows Of Harvard College Integrated human organ-on-chip microphysiological systems
EP2792368A4 (de) 2011-12-12 2015-09-30 Kyowa Hakko Kirin Co Ltd Lipid-nanopartikel mit kombinationen aus kationischen lipiden
WO2013089151A1 (ja) 2011-12-12 2013-06-20 協和発酵キリン株式会社 カチオン性脂質を含有するドラッグデリバリーシステムのための脂質ナノ粒子
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
SG10201601349XA (en) 2011-12-13 2016-03-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
EP2604253A1 (de) 2011-12-13 2013-06-19 Otto Glatter Wasser-in-Öl-Emulsionen und Verfahren zu deren Herstellung
US20150000936A1 (en) 2011-12-13 2015-01-01 Schlumberger Technology Corporation Energization of an element with a thermally expandable material
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
US9636414B2 (en) 2011-12-15 2017-05-02 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
WO2013090897A1 (en) 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
US20130157963A1 (en) 2011-12-16 2013-06-20 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers
WO2013090601A2 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Compact nanoparticles for biological applications
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
IN2014DN05912A (de) 2011-12-16 2015-06-05 Massachusetts Inst Technology
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9744318B2 (en) 2011-12-16 2017-08-29 Novartis Ag Aerosolization apparatus for inhalation profile-independent drug delivery
US9546235B2 (en) 2011-12-19 2017-01-17 The University Of Sydney Peptide-hydrogel composite
US9241829B2 (en) 2011-12-20 2016-01-26 Abbott Medical Optics Inc. Implantable intraocular drug delivery apparatus, system and method
JP2015510495A (ja) 2011-12-21 2015-04-09 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 器官または器官移植片の生存可能性または寿命を延長する方法
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013101908A1 (en) 2011-12-27 2013-07-04 Massachusetts Institute Of Technology Microneedle devices and uses thereof
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
EP3735967A1 (de) 2012-01-06 2020-11-11 NeuroBo Pharmaceuticals, Inc. Verbindung zur verwendung in verfahren zur verringerung des risikos einer kardiovaskulären erkrankung
KR20140129054A (ko) 2012-01-26 2014-11-06 라이프 테크놀로지스 코포레이션 바이러스의 감염성을 증가시키는 방법
SG11201404014PA (en) 2012-01-26 2014-08-28 Life Technologies Corp Methods for increasing the infectivity of viruses
EP2623121A1 (de) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmazeutische Zusammensetzung mit einem Polymerträger-Cargo-Komplex und einem Antigen
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
CN104245745B (zh) 2012-02-09 2017-03-29 生命技术公司 亲水性聚合物颗粒及其制备方法
US20140037573A1 (en) 2012-02-22 2014-02-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20130243867A1 (en) 2012-02-23 2013-09-19 University Of South Florida (A Florida Non-Profit Corporation) Micelle compositions and methods for their use
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
WO2013136234A1 (en) 2012-03-13 2013-09-19 University Of Kwazulu-Natal Transdermal delivery devices
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
CN104363924B (zh) 2012-03-16 2018-04-17 约翰霍普金斯大学 用于递送hif‑1抑制剂的控制释放调配物
WO2013135359A1 (en) 2012-03-16 2013-09-19 Merck Patent Gmbh Targeting aminoacid lipids
US9610346B2 (en) 2012-03-23 2017-04-04 International Aids Vaccine Initiative Recombinant viral vectors
WO2013142349A1 (en) 2012-03-23 2013-09-26 University Of Chicago Compositions and methods related to staphylococcal sbi
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9717685B2 (en) 2012-03-26 2017-08-01 President And Fellows Of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
SG11201405545XA (en) 2012-03-27 2014-11-27 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
CA2867323C (en) 2012-03-27 2020-07-07 Sirna Therapeutics, Inc. Diether based biodegradable cationic lipids for sirna delivery
CA2859452C (en) 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
EP2830596B1 (de) 2012-03-29 2020-12-30 Translate Bio, Inc. Aus lipiden gewonnene neutrale nanopartikel
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3501550A1 (de) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EP2833926A4 (de) 2012-04-05 2015-11-25 Univ Florida Neurophile nanopartikel
EP2833918B1 (de) 2012-04-05 2019-05-08 Massachusetts Institute of Technology Immunstimulationszusammensetzungen und verfahren zur verwendung davon
WO2013152351A2 (en) 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
CN104379127A (zh) 2012-04-08 2015-02-25 席拉蔻公司 制备用于治疗泌尿上皮失调的热可逆凝胶制剂
ES2560235T3 (es) 2012-04-11 2016-02-18 Intezyne Technologies Inc. Copolímeros en bloque para micelas estables
WO2013155493A1 (en) 2012-04-12 2013-10-17 Yale University Methods of treating inflammatory and autoimmune diseases and disorders
WO2013154766A1 (en) 2012-04-13 2013-10-17 New York University Microrna control of ldl receptor pathway
US11001797B2 (en) 2012-04-13 2021-05-11 President And Fellows Of Harvard College Devices and methods for in vitro aerosol delivery
CN103764153A (zh) 2012-04-18 2014-04-30 箭头研究公司 用于体内核酸递送的聚(丙烯酸酯)聚合物
US9402816B2 (en) 2012-04-19 2016-08-02 Sima Therapeutics, Inc. Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
WO2013163234A1 (en) 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
IN2014DN09134A (de) 2012-04-25 2015-05-22 Regulus Therapeutics Inc
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
WO2013173657A1 (en) 2012-05-16 2013-11-21 Micell Technologies, Inc. Low burst sustained release lipophilic and biologic agent compositions
US9399672B2 (en) 2012-05-17 2016-07-26 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Hepatitis C virus neutralizing antibody
WO2013173693A1 (en) 2012-05-18 2013-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoparticles with enhanced entry into cancer cells
KR20150032945A (ko) 2012-05-23 2015-03-31 더 오하이오 스테이트 유니버시티 지질-코팅된 알부민 나노입자 조성물 및 이를 제조하는 방법 및 사용하는 방법
US20150306249A1 (en) 2012-05-25 2015-10-29 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
CN104363949B (zh) 2012-06-06 2018-06-05 洛马维斯塔医药股份有限公司 可胀大的医疗装置
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
PL2858974T3 (pl) 2012-06-08 2019-03-29 Nitto Denko Corporation Lipidy do preparatów do dostarczania środka terapeutycznego
EP2858677B1 (de) 2012-06-08 2020-08-05 ethris GmbH Pulmonale verabreichung von mrns
CA2877051C (en) 2012-06-20 2021-09-21 Frank Gu Mucoadhesive nanoparticle delivery system
WO2014014613A2 (en) 2012-06-20 2014-01-23 President And Fellows Of Harvard College Self-assembling peptides, peptide nanostructures and uses thereof
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
US9956291B2 (en) 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
EP2872120B1 (de) 2012-07-16 2017-05-03 Nanoderm Sciences, Inc. Therapeutische nanopartikel mit einem polymyxin b targetig mittel
EP2687251A1 (de) 2012-07-17 2014-01-22 Sanofi-Aventis Deutschland GmbH Arzneimittelabgabevorrichtung
EP2687252A1 (de) 2012-07-17 2014-01-22 Sanofi-Aventis Deutschland GmbH Arzneimittelabgabevorrichtung
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014015334A1 (en) 2012-07-20 2014-01-23 Brown University System and methods for nanostructure protected delivery of treatment agent and selective release thereof
EP2877600B1 (de) 2012-07-24 2019-04-10 President and Fellows of Harvard College Selbstanordnung von nukleinsäurenanostrukturen
GB201213624D0 (en) 2012-07-27 2012-09-12 Univ Ulster The Method and system for production of conjugated nanoparticles
WO2014015422A1 (en) 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2014024193A1 (en) 2012-08-07 2014-02-13 Prodel Pharma Ltd. Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients
US9931418B2 (en) 2012-08-07 2018-04-03 Northeastern University Compositions for the delivery of RNA and drugs into cells
US9974886B2 (en) 2012-08-08 2018-05-22 Nanyang Technological University Methods of manufacturing hydrogel microparticles having living cells, and compositions for manufacturing a scaffold for tissue engineering
EP2882474A4 (de) 2012-08-08 2016-05-11 Presage Biosciences Inc Extrusionsverfahren und vorrichtungen zur wirkstofffreisetzung
CN104736181A (zh) 2012-08-10 2015-06-24 北德克萨斯大学健康科学中心 包含靶向聚氨基酸与脂肪酸之缀合物的药物递送载剂
WO2014027006A1 (en) 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Bioadhesive formulations for use in drug delivery
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
CA2881605A1 (en) 2012-08-14 2014-02-20 Aaron FROESE Internal structured self assembling liposomes
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
CA2882248A1 (en) 2012-08-15 2014-02-20 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
WO2014039185A1 (en) 2012-09-05 2014-03-13 Creighton University Polymeric nanoparticles in a thermosensitive gel for coital-independent vaginal prophylaxis of hiv
US8703197B2 (en) 2012-09-13 2014-04-22 International Business Machines Corporation Branched polyamines for delivery of biologically active materials
PL2895156T3 (pl) 2012-09-17 2019-09-30 Pfizer Inc. Sposób wytwarzania nanocząstek terapeutycznych
WO2014047649A1 (en) 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
CA2925687A1 (en) 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2903595A1 (de) 2012-10-04 2015-08-12 University Of The Witwatersrand, Johannesburg System zur verabreichung liposomaler arzneimittel
EP2716655A1 (de) 2012-10-04 2014-04-09 Institut Pasteur Neue neutralisierende Antikörper, die sich gegen den Hepatitis C-Virus richten
US20140100178A1 (en) 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2716689A1 (de) 2012-10-05 2014-04-09 National University of Ireland, Galway Polymer mit einer Vielzahl von Zweigstellen die zumindest eine Disulfideinheit und/oder eine Vinylgruppe aufweisen
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
WO2014059022A1 (en) 2012-10-09 2014-04-17 The Brigham And Women's Hospital, Inc. Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
US20140106260A1 (en) 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Core-shell nanoparticulate compositions and methods
EP2908818A4 (de) 2012-10-16 2016-07-13 Endocyte Inc Wirkstofffreisetzungskonjugate mit unnatürlichen aminosäuren und verfahren zur verwendung
IL301018A (en) 2012-10-18 2023-05-01 Univ Rockefeller Broad-spectrum neutralizing antibodies against the AIDS virus
WO2014066912A1 (en) 2012-10-26 2014-05-01 Vanderbilt University Polymeric nanoparticles
US20150272900A1 (en) 2012-10-26 2015-10-01 The Johns Hopkins University Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics
AU2013336582A1 (en) 2012-10-26 2015-06-11 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types
WO2014067551A1 (en) 2012-10-29 2014-05-08 Technische Universität Dortmund T7 rna polymerase variants and methods of using the same
EP2914728B1 (de) 2012-11-01 2020-07-08 Factor Bioscience Inc. Verfahren und produkte zur expression von proteinen in zellen
WO2014071072A2 (en) 2012-11-02 2014-05-08 Pungente Michael D Novel cationic carotenoid-based lipids for cellular nucleic acid uptake
WO2014068542A1 (en) 2012-11-05 2014-05-08 Fondazione Centro San Raffaele Novel targets in multiple myeloma and other disorders
BR112015010253A2 (pt) 2012-11-06 2017-07-11 Rochal Ind Llc entrega de agentes biologicamente ativos com o uso de solventes hidrofóbicos e voláteis
WO2014074597A1 (en) 2012-11-06 2014-05-15 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
US9572893B2 (en) 2012-11-07 2017-02-21 Council Of Scientific And Industrial Research Nanocomplex containing cationic peptide for biomolecule delivery
EP2916873B1 (de) 2012-11-07 2017-07-26 Council of Scientific & Industrial Research Nanokomplex mit amphipatischen peptiden zur effizienten transfektion von biomolekülen
CN104903349B (zh) 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
TW201428101A (zh) 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
AU2013343864B2 (en) 2012-11-09 2019-04-04 BioNTech SE Method for cellular RNA expression
EP2916853B1 (de) 2012-11-09 2020-05-06 Velin-Pharma A/S Zusammensetzungen zur pulmonalen verabreichung
US9200119B2 (en) 2012-11-09 2015-12-01 Momentive Performance Materials Inc. Silicon-containing zwitterionic linear copolymer composition
EP2916862B1 (de) 2012-11-12 2020-01-08 GenVec, Inc. Malariaantigene und verfahren zur verwendung
GB201220354D0 (en) 2012-11-12 2012-12-26 Medpharm Ltd Dermal compositions
KR20150083121A (ko) 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
US9943608B2 (en) 2012-11-13 2018-04-17 Baylor College Of Medicine Multi-arm biodegradable polymers for nucleic acid delivery
WO2014078636A1 (en) 2012-11-16 2014-05-22 President And Fellows Of Harvard College Nucleic acid hydrogel self-assembly
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2732825B1 (de) 2012-11-19 2015-07-01 Invivogen Konjugate eines TLR7- und/oder TLR8-Agonisten mit einem TLR2-Agonisten
CN104853747B (zh) 2012-11-19 2020-06-19 理工研究与开发基金公司 用于体内递送的脂质体
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081303A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
EP2971010B1 (de) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3981437A1 (de) 2014-04-23 2022-04-13 ModernaTX, Inc. Nukleinsäureimpfstoffe

Also Published As

Publication number Publication date
DK3682905T3 (da) 2022-02-28
RU2014117701A (ru) 2015-11-10
EP2763701A1 (de) 2014-08-13
MX354267B (es) 2018-02-21
IL262667B (en) 2020-02-27
JP7019639B2 (ja) 2022-02-15
JP2017113029A (ja) 2017-06-29
AU2019219843A1 (en) 2019-09-12
WO2013052523A1 (en) 2013-04-11
EP2763701A4 (de) 2015-12-16
CA2850624A1 (en) 2013-04-11
AU2021201508A1 (en) 2021-04-01
HK1200730A1 (en) 2015-08-14
ES2911677T3 (es) 2022-05-20
CN103974724B (zh) 2019-08-30
IL231808B (en) 2018-11-29
IL262667A (en) 2018-12-31
PT3682905T (pt) 2022-04-07
KR102014061B1 (ko) 2019-08-28
RU2018104839A (ru) 2019-02-22
JP2022060269A (ja) 2022-04-14
NZ623476A (en) 2016-09-30
EP3682905A1 (de) 2020-07-22
EP4015005A1 (de) 2022-06-22
HUE057725T2 (hu) 2022-06-28
US20170056528A1 (en) 2017-03-02
EP3492109A1 (de) 2019-06-05
CY1125029T1 (el) 2023-03-24
JP2019208511A (ja) 2019-12-12
US9428535B2 (en) 2016-08-30
JP2014530601A (ja) 2014-11-20
AU2017213503B2 (en) 2019-06-20
EP3682905B1 (de) 2021-12-01
HRP20220250T1 (hr) 2022-04-29
IL231808A0 (en) 2014-05-28
BR112014007852A2 (pt) 2017-04-18
JP2018166528A (ja) 2018-11-01
JP6113737B2 (ja) 2017-04-12
RU2648950C2 (ru) 2018-04-02
EP2763701B1 (de) 2018-12-19
US20130123481A1 (en) 2013-05-16
AU2017213503A1 (en) 2017-08-31
JP6574032B2 (ja) 2019-09-11
EP3492109B1 (de) 2020-03-04
KR20140068245A (ko) 2014-06-05
MX2014003979A (es) 2014-08-26
RU2707251C2 (ru) 2019-11-25
SG10201602654SA (en) 2016-05-30
SG11201401196WA (en) 2014-05-29
AU2012318752B2 (en) 2017-08-31
SI3682905T1 (sl) 2022-04-29
CN103974724A (zh) 2014-08-06
JP2024036694A (ja) 2024-03-15
PL3682905T3 (pl) 2022-04-04
US20210308283A1 (en) 2021-10-07
CN110511939A (zh) 2019-11-29
RS62993B1 (sr) 2022-03-31
LT3682905T (lt) 2022-02-25
US20130115272A1 (en) 2013-05-09
JP6388977B2 (ja) 2018-09-12
KR20190099538A (ko) 2019-08-27
AU2023200127A1 (en) 2023-02-16
RU2018104839A3 (de) 2019-02-22
AU2012318752A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
DE19216461T1 (de) Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
DE3546806C2 (de)
DE3043981C2 (de)
DE69433648T2 (de) Menschliche chemokin-polypeptide
DE18200782T1 (de) Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
DE20023125U1 (de) Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60318026T2 (de) Hybrid-hepatozyten-wachstumsfaktorgen mit hoher expressionseffizienz von zwei hepatozyten-wachstumsfaktor-heterotypen
Rosenberg et al. Eosinophils, ribonucleases and host defense: solving the puzzle
EP0585681A2 (de) Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
EP1320747B1 (de) Medium für analytische und präparative elektrophorese
WO2003062432A1 (de) Verfahren zur erhöhung der wirksamkeit eines inhibitors der aktivität einer tyrosinkinase
DE112005000737T5 (de) Mit Heparansulfat-Zuckerketten modifizierte Heparin-bindende Proteine, Verfahren zur Erzeugung derselben und Arzneimittel, welche dieselben enthalten
DE69534044T2 (de) Menschliches beta-9 chemokin
WO2002055721B1 (de) Modulare transfektionssysteme auf der basis von nukleoproteinfilamenten
DE10100587C1 (de) Verfahren zur Hemmung der Expression eines Zielgens
DE19906096A1 (de) Protein mit einem Heparin-bindenden Epitop
Carvalho-Paulo et al. Microglial morphology across distantly related species: phylogenetic, environmental and age influences on microglia reactivity and surveillance states
DE10704945T1 (de) Verbesserte konstruktion von small-interfering-rna
DE4036856C1 (de)
DE69631516T2 (de) Familie von Kaliumkanälen von Säugetieren, deren Klonierung und Anwendung für Drogenscreening
DE69333350T2 (de) Methode zur selektion von nukleinsäuren auf der basis ihrer struktur
DE3544459C2 (de) Verfahren zum Synthetisieren von langkettiger Desoxyribonucleinsäure (DNA)
DE69533804T2 (de) Mimetika von aus alternden Zellen abgeleiteten Hemmern der DNA-Synthese
EP2978402A1 (de) Stabilisiertes polyribonucleotid codierend für ein elastisches faserprotein
AT506151B1 (de) Fusionsprotein